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Abstract 
 
 
There is increasing evidence for a role of acetylcholine in modulating the inflammatory 
response. This has been demonstrated to occur predominantly via the ‘cholinergic anti-
inflammatory pathway’ and mediated by the α7 nicotinic acetylcholine receptor 
(α7nAChR). Therefore, there is now an abundance of in vitro and in vivo evidence that 
suggest pharmacologically target the α7nAChR is a potential anti-inflammatory therapy 
to treat chronic inflammatory diseases. The role of acetylcholine and the α7nAChR in 
modulating the periodontal immune response is at present unknown. However, as nu-
merous cells within the periodontium express the α7nAChR it is interesting to speculate 
that targeting this receptor may modulate the periodontal immune response. Therefore, 
his study aims to investigate the effects of the α7nAChR on the periodontal pathogen 
(P. gingivalis) induced expression of Interleukin-8 (IL-8) by oral keratinocytes.  
Expression of the α7nAChR mRNA was demonstrated to be upregulated in diseased 
periodontal tissue. In line with previous studies, oral keratinocytes were found to ex-
press the α7nAChR using PCR. The acetylcholine mimic; Carbachol when used in high 
concentrations was found to inhibit dead P. gingivalis induced IL-8 expression by 
OKF6-TERT2 cells in vitro. The expression of IL-8 was investigated at both the protein 
level by ELISA and the transcriptional level by real time PCR. In contrast, the specific 
α7nAChR agonist (PHA 543613 hydrochloride) when used at pharmacological concen-
trations potently inhibited expression of IL-8 by OKF6-TERT2 cells cultured with a live 
P. gingivalis biofilm. This was again determined using ELISA and real time PCR. A 
membrane integrity assay confirmed that the agonist exhibited no toxic effects on the 
cells. The inhibition of IL-8 expression was found to be mediated at the transcriptional 
level. Indeed, using a Fast Activated Cell-based ELISA (FACE) NF-κB p65 Profiler Kit 
activation of the α7nAChR inhibited the phosphorylation of the NF-κB p65 subunit at 
Serine 468 and serine 536. Therefore, it can be hypothesised that targeting the 
α7nAChR leads to inhibition of NF-κB p65 subunit translocation into the nucleus and 
thus downregulated IL-8 transcription. 
These data suggest that the α7nAChR plays a role in regulating the pathogen induced 
immune response at epithelial surfaces. As dysregulated immunity is a hallmark of peri-
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odontal disease it is interesting to speculate that pharmacologically targeting the 
α7nAChR may offer a novel immune-modulatory therapy. 
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Definitions 
 
AC                     Adenyl cyclase 
ACh                   Acetylcholine 
AChE                Acetylcholine esterase 
AcCoA              Acetyl co-enzyme A 
α7nAChR          Alpha7 nicotinic acetylcholine receptor 
BChE                 Butyrylcholinesterase 
BPE                   Bovine pituitary extract 
cAMK               Ca2+ calmodulin dependent protein kinase 
Car                    Carbachol 
ChAT                choline acetyl transferase 
CHT1                 high-affinity choline transporter-1 
CIA                   collagen-induced arthritis 
CREB                cAMP response element-binding protein (CREB) 
CTLA-4-Ig        cytotoxic T-lymphocyte antigen 4 immunoglobin  
DKSFM            defined serum-free medium 
DMEM              Dulbecco’s modified eagle medium 
E. coli                Escherichia coli 
EGF                   epithelial growth factor 
ELISA               enzyme-linked immunosorbant assay 
ERK                  extracellular signal regulated mitogen activated protein kinase 
FAA                  Fastidious anaerobic agar 
FACE                Face activated cell-based ELISA 
FCS                   foetal calf serum 
FLS                   fibroblast-like synoviocytes 
FoxP3                forkhead box protein 3 
GAS                  Gamma activated sequence 
GCF                  Gingival crevicular fluid 
HMGB1            high mobility group box protein 1 
IL                      interleukin 
IκBα                  inhibitor of kappa B alpha 
JAK2                 janus kinase 2 
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K-SFM              keratinocyte serum free medium 
LDH                  Lactate dehydrogenase 
LPS                   lipopolysaccharide 
mAChR            muscarinic receptors 
MIP-1α             macrophage inflammatory protein 1 alpha 
MMPs              matrix metalloproteinases 
nAChR             nicotinic receptors 
NAK                NF-κB activating kinase 
NF-κB               nuclear factor kappa light chain enhancer of activated B cells 
OCTs                organic cation transporters 
OPG                  osteoprotegerin 
PCR                  polymerase chain reaction   
PD                     periodontal disease 
Pg                     Porphyromonas gingivalis 
PI3K                 phosphotidyl inositol 3-kinase 
PKA                  protein kinase A 
PKC                  protein kinase C 
OPG- FC          osteoprotegerin-fragment crystallisable region  
RANKL            receptor activator of nuclear factor kappa-B ligand 
STAT3              signal transducer and activator of transcription 3 
TBK1                TANK-binding kinase-1 
TLR2                 toll-like receptor 2 
TNF-α               tumor necrosis factor alpha 
VAChT             vesicular acetylcholine transporter 
 
M                       Molar 
mg                      milligram 
ml                      milliliter 
µg                      microgram 
mM                   millimolar 
µM                    micromolar 
nM                     nanomolar 
MOI                  multiplicity of infection 
g                        gram 
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CFU                  colony forming unit 
5HT-3               5-hydroxytryptamine 
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1.1 Periodontal Disease: 
 
Periodontal disease (PD) is a chronic, destructive, inflammatory disease which left un-
treated leads to tooth mobility, loss of dental function and ultimately tooth loss. PD is an 
important clinical problem which affects an estimate of 8 - 15% of the UK population 
(Kelly M, 1998) and represents a significant cost burden to the NHS; where its treat-
ment costs the NHS in Scotland alone at least £20 million annually 
(www.isdscotland.org). In addition, there is now a multitude of evidence which demon-
strate bi-directional links between PD and other chronic inflammatory conditions such 
as rheumatoid arthritis (Teng, 2003, Rosenstein et al., 2004, Pischon et al., 2008, Zelkha 
et al., 2010). At present, the pathogenesis of PD has yet to be fully elucidated although 
key cellular and molecular mechanisms have been identified which contribute to the tis-
sue destruction and bone loss which are the clinical hallmarks of the disease. However, 
more research is still needed in order to develop better diagnostic tests and novel thera-
peutic tools to treat the condition. 
 
 
1.2 Dental Plaque 
 
PD progression results from a complex interplay of bacterial infection and host response 
and is modified by behavioral and systemic risk factors. In the mid 1960’s, dental 
plaque accumulation was demonstrated to be one of the major etiologic factors in PD 
pathogenesis (Löe et al., 1965). Clinical studies have demonstrated that regular removal 
of dental plaque from oral surfaces is a primary prerequisite to prevent disease (Löe et 
al., 1965, Lindhe et al., 2008). 
 
Dental plaque results from the accumulation and metabolism of bacterial deposits on the 
tooth surfaces in the oral cavity. Dental plaque may accumulate supragingivally, i.e. on 
the clinical crown of the tooth, but also subgingivally, or in the subgingival area of the 
sulcus. Due to differences in local blood supply, pocket depths and oxygen tension, bac-
terial composition of plaque can vary greatly depending on the site of accumulation 
(Socransky et al., 1987). Interestingly however, in a 1 mm
3
 section of dental plaque 
weighing approximately 1 mg, more than 10
8 
bacteria can be present made up from over 
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300 different species (Lindhe et al., 2008). This bacterial mass was shown to produce a 
variety of irritants, such as endotoxins, acids and antigens, which over time lead directly 
to the destruction of teeth supporting tissues.  
 
Socransky grouped the bacteria found within dental plaque into colour coded complexes 
according to species co-localisation within a biofilm and their relative pathogenicity 
(Socransky and Haffajee, 2005). In health, the oral cavity consists mainly of species in-
cluding: Actinomyces (blue complex) and Veillonella (Purple complex), all of which 
associate closely with members of the yellow complex; the streptococcal spp 
(Socransky and Haffajee, 2005). The orange complexes consist of species such as 
Fusobacterium nucleatum, and Prevotella intermedium. The green complex consists of 
species such as Campylobacter concisus and Aggregatibacter actinomycetemcomitans. 
The red complex is usually found around periodontal pockets and consists of bacteria 
such as Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola. The 
red complexes and the green complexes have been shown to associate closely with 
members of the orange clusters (Socransky and Haffajee, 2005, Haffajee et al., 2008, 
Lindhe et al., 2008). Indeed, it is these red complex species that play key roles in the 
pathogenesis of periodontal disease (Berglundh et al., 1999).  
  
Porphyromonas gingivalis (P. gingivalis) has been proved in many studies to be one of 
the main causative organisms of chronic periodontitis (Socransky et al., 1998). A broad 
range of virulence factors are produced by P. gingivalis, all of which contribute to the 
host inflammatory response  (Birkedal-Hansen, 1993, Okada and Murakami, 1998).The 
most potent virulent factors are the gingipains, which consist of three cysteine proteases 
that are responsible for at least 85 % of the total proteolytic activity of this pathogen 
(Amano, 2010). Gingipain activity is essential in sequential phases of the disease pro-
cess: from attachment and colonization, through nutrient acquisition, neutralisation of 
host defenses and manipulation of inflammatory response, to tissue destruction, inva-
sion and dissemination to systemic sites (Amano, 2010).  Other virulence factors in-
clude lipopolysaccharide (LPS), which is the major macromolecule found on the outer 
surface of gram-negative bacteria.  The lipopolysaccharide of P. gingivalis is unusual in 
that it performs weakly in endotoxin assays, although it is quite mitogenic. However, 
this may be because it is structurally different from other gram-negative bacteria 
(Condorelli et al., 1998, Hamada et al., 1994, Hirose et al., 1997).  P. gingivalis LPS 
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provokes an innate immune response when recognized by the human host as a foreign 
molecule. It is well established that Lipid A, the bioactive region of LPS that is recog-
nized by the innate immune response, engages the Toll-like receptor 4 (TLR-4) com-
plex, triggering the proinflammatory cytokine production. However, P. gingivalis LPS 
can also induce Toll-like receptor 2 (TLR-2) which plays a potent role in initiating a 
destructive immune response (Jain and Darveau, 2010). Moreover, Darveau et al. have 
investigated the ability of P. gingivalis lipopolysaccharide to stimulate the inflammatory 
response directly by its interaction with endothelial cells (Darveau et al., 1995). P. gin-
givalis also possess fimbrae (fimA) which have been implicated in the ability to attach 
and interact with epithelial cells, fibroblasts, and other bacteria. Furthermore, it has been 
shown that P. gingivalis can produce enzymes called chondroitinase and heparitinase 
that aid in its permeation into the gingival epithelium (Smith et al., 1997). This permea-
tion will result in the ingress of more microbial virulence factors into the periodontal 
tissues thereby resulting in localised tissue destruction in PD (Smith et al., 1997). 
Our understanding of dental plaque structure, growth and the diversity have greatly en-
hanced by the recent developments in microbiology, molecular biology and microbial 
genomics (Preshaw and Taylor, 2011). Plaque formation occurs in different phases. It 
begins with acquired pellicle formation on the tooth surface through molecular adsorp-
tion (Lindhe et al., 2008). This thin pellicle is composed of different salivary mucins 
and antibodies and can act as a substrate for bacterial colonisation. In the first phase of 
colonisation the first organisms to bind to this pellicle are the streptococcal species 
(primary colonizers), followed by members of the blue and purple complexes. The 
primitive film then provides a perfect niche for other bacteria to complex and the as-
sembly of a biofilm begins (Bakaletz, 2004). The orange complexes are the intermediate 
colonisers that bind primary colonisers via specific surface receptors and adhesion mol-
ecules (Socransky and Haffajee, 2005, Haffajee et al., 2008, Lindhe et al., 2008). Once 
attached, the behavior of the existing bacteria changes leading to active cellular growth 
of previously starving bacteria and synthesis of new outer membrane components 
(Lindhe et al., 2008). Members of the green and red complexes then can bind to the in-
termediate colonisers. These complexes contain the periodontopathic bacteria that are 
readily found in patients with periodontal disease (Socransky and Haffajee, 2005, 
Haffajee et al., 2008, Lindhe et al., 2008). During the last phase of biofilm formation 
(maturation) the bacterial mass increases due to continued multiplication of adhering 
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microorganisms and adhesion of new bacteria (Lindhe et al., 2008). The plaque biofilm 
is a perfect ecological niche for periodontopathic bacteria as it facilitates exchange of 
nutrients and helps the organisms to survive and proliferate.  
The dental biofilm provides protection from the host defense mechanisms by firmly ad-
hering to the tooth surface and thereby provide an advantage over free-floating (plank-
tonic) bacteria (Lee and Wang, 2010, Hannig and Hannig, 2009, Fritz, 1999, Fürst et al., 
2007, Listgarten, 1994, Munson et al., 2002). In addition, the biofilm provides physical 
protection from some antimicrobial agents, thus making PD difficult to treat. The extra-
cellular matrix produced by biofilm bacteria encloses the microbial community and pro-
tects it from the surrounding environment, including attacks from chemotherapeutic 
agents such as antibiotics and antiseptics. Furthermore, the extracellular matrix keeps 
the bacteria banded together, so they are not flushed away by the action of saliva and 
gingival crevicular fluid. Mechanical methods, including toothbrushing, interdental 
cleaning, and professional scaling procedures, are required to regularly and effectively 
disrupt and remove the plaque biofilm. Antiseptics, such as mouthrinses, can help to 
control the biofilm but must be formulated so as to be able to penetrate the plaque ma-
trix and gain access to the pathogenic bacteria. Therefore the complex nature of the 
plaque biofilm provides the perfect shelter for periodontal pathogens. These pathogens 
can express a plethora of virulence determinants that can penetrate the sulcular epitheli-
um and modulate the host immune response (Marsh, 2004).  
 
1.3   Host immune response in Periodontal Disease: 
 
A widely accepted view is that in an attempt to remove the pathogenic microflora of 
dental plaque the host mounts an immune response which in susceptible individuals be-
comes dysregulated. Instead of clearing the pathogenic threat the dysregulated immune 
response leads to bystander damage such as the breakdown of connective tissue and 
bone loss which are the clinical hallmarks of periodontal disease (Graves, 2008). In re-
sponse to threat, immune-competent oral keratinocytes and resident macrophages be-
come excessively activated and orchestrate the infiltration of neutrophils and other in-
flammatory cells into the oral mucosal tissue. As part of this process increased angio-
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genesis occurs which helps to support the inflammatory infiltrate. If these inflammatory 
processes are not effectively regulated it can lead to the creation of a hyper-
inflammatory environment characterised by excessive production of immuno-
modulatory mediators including; cytokines, chemokines, prostanoids, antimicrobials 
and enzymes.  Many of these mediators, such as the matrix metalloproteinase (MMPs) 
and antimicrobial peptides play direct roles in localised tissue destruction. In addition, 
many inflammatory mediators regulate the processes of bone remodeling. Indeed a hy-
per-inflammatory environment can perturb the balance between bone formation (osteo-
blastogenesis) and bone resorption (osteoclastogenesis) leading to loss of the alveolar 
bone which supports the teeth. Therefore the prominent role of the inflammatory re-
sponse in periodontal disease pathogenesis suggests that host response modulation may 
provide novel therapeutic interventions for treatment (Preshaw, 2008). 
 
 
1.4   Interleukin 8 
 
Much research has been focused on the role of the chemokine Interleukin 8 (IL-8) in 
PD. IL-8 (CXCL8) is a pro-inflammatory chemokine produced by various cells such as 
monocytes, neutrophils, fibroblasts, lymphocytes, endothelial cells (Gainet et al., 1998, 
Soehnlein and Lindbom, 2010). The important role of IL-8 in periodontal disease path-
ogenesis is elucidated by the fact that large amounts can be detected in the gingival 
crevicular fluid (GCF) of periodontal disease patients (Mathur et al., 1996) and in the 
gingival tissues in areas exposed to dental plaque (Tonetti et al., 1994). In addition, lev-
els of IL-8 in the gingival crevicular fluid (GCF) have been shown to relate to clinical 
signs of PD such as the loss of attachment (Jarnbring et al., 2000).  
 
IL-8 has been shown to be expressed by oral keratinocytes (Fitzgerald and Kreutzer, 
1995) and its expression is up regulated in these cells by cytokines such as IL-1β and 
TNF-α (Schluger and Rom, 1997) as well as direct interactions with bacteria (Tonetti, 
1997) and bacterial LPS (Taguchi and Imai, 2006). In addition, it has been demonstrat-
ed in many studies that infection of oral keratinocytes by P. gingivalis can induce IL-8 
production in oral epithelial cells (Handfield et al., 2008, Darveau, 2009).  
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Within the periodontium, the up regulated expression of IL-8 by resident epithelial cells 
and immune cells initiates a chemotactic IL-8 gradient which is essential for neutrophil 
migration (Tonetti, 1997). Therefore, the primary function of IL-8 is the recruitment and 
activation of neutrophils (Gainet et al., 1998, Soehnlein and Lindbom, 2010) and there-
by the orchestration of the innate immune response in PD. IL-8 binds to neutrophils 
through the G-protein coupled receptor CXCR2 (Soehnlein and Lindbom, 2010, Gainet 
et al., 1998). Once CXCR2 is activated it exerts various effects on neutrophils’ includ-
ing supporting adhesion to endothelial cells, initiating morphological changes to aid 
transmigration across tissues, exocytosis of primary and secondary granules containing 
lysosomal enzymes and initiating a respiratory burst in order to aid microbial clearance 
(Bickel, 1993).  
 
Although IL-8 is required for an effective immune response to periodontal pathogens, it 
is important that its expression is regulated as excessive levels can be detrimental to the 
host.  Excess IL-8 can induce tissue damage as it is a potent inducer of matrix metallo-
proteinases (MMP) expression (Heath et al., 1985, Gowen and Mundy, 1986). MMP’s 
represent the most prominent proteinase family associated with PD (Folgueras et al., 
2004) and play key roles in remodeling tissue of the periodontium in periodontitis. The 
23 MMP’s in humans are genetically distinct but structurally similar zinc-dependent 
metalloendopeptidases. They can be classified into different subgroups based on their 
primary structures and substrate specifities (Hernández et al., 2011). MMP’s can be di-
vided into collagenases (MM-1, -8 and -13), gelatinases (MMP-2 and -9) and strome-
lysins (MMP-3, -10 and -11) (Bildt et al., 2009). GCF analysis established that during 
the active stage of PD, neutrophil-derived MMP- 8 and MMP-9 are actively present 
(Lee et al., 1995). MMPs can synergistically degrade almost all extracellular matrix and 
basement membrane components and regulate several cellular processes, including in-
flammatory and immune responses. It has been found in different studies that IL-8 plays 
an important role in the production of MMP-9 through the degranulation of neutrophil 
(Sorsa et al., 2006). MMP-1 plays an important role in hydrolyzing type III collagen, 
and together with MMP-8, it has a potent effect during the initiation of collagen degra-
dation in PD (Birkedal-Hansen, 1993, Ingman et al., 1994, Golub et al., 1997).  Moreo-
ver, high levels of IL-8 in the periodontium can indirectly stimulate osteoclast differen-
tiation and function. This occurs through enhancement of RANKL (Receptor activator 
of nuclear factor kappa-B ligand) expression and suppression of osteoprotegerin (OPG) 
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expression by osteoblasts (Koide et al., 2010, Kajiya et al., 2010). RANKL activates 
osteoclasts which can ultimately promote bone loss.  
 
Because of its proinflammatory and neutrophil chemoattractant properties, IL-8 has 
been considered to play a significant role in the early stages of periodontal disease path-
ogenesis. Therefore, it is interesting to speculate that IL-8 may be a rational target for 
therapeutic interventions. 
 
1.5   Acetylcholine 
 
ACh is widely distributed in prokaryotic and eukaryotic cells. To date, despite its ubiq-
uitous expression, research into the biological role of ACh has primarily focused on its 
neurotransmitter function. However, as early as 1963 Whittaker stated that: ‘acetylcho-
line occurs in non-nervous tissues and is widely distributed in nature to suggest a non-
nervous function of it ((VP, 1963). Thus, the biological role of ACh in humans has had 
to be revised to accommodate two roles: neuronal ACh acting as a neurotransmitter to 
mediate rapid communication between neurons and effector cells and non-neuronal 
ACh acting as a local signaling molecule involved in the regulation of cellular pheno-
types. (Wessler and Kirkpatrick, 2008).  
 
Knowledge of the synthesis, storage, metabolism and actions of ACh has been derived 
mostly from studies of the mammalian nervous system (Kawashima and Fujii, 2008) 
and our current understanding is demonstrated in Figure 1. In brief, ACh is synthesized 
predominantly by choline acetyltransferase (ChAT) from choline and acetyl coenzyme 
A (AcCoA). AcCoA is the major product of carbohydrate, protein and lipid catabolism 
in aerobic organisms and is thus present in more or less all cells. Choline on the other 
hand originates from the intracellular breakdown of choline containing phospholipids or 
from the uptake of extracellular choline via low- or high- affinity choline transporter 1 
(CHT1). At nerve terminals, ACh is taken up by the vesicular acetylcholine transporter 
(VAChT) and stored in characteristic small, optically clear vesicles. ACh is then re-
leased from nerve terminals by exocytosis. Release studies using the human placenta as 
a model of the non-neuronal cholinergic system, due to the fact it lacks nervous innerva-
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tion, have also demonstrated that non-neuronal ACh is actively released despite the tis-
sue being less well endowed with cholinergic vesicles.  However, the mechanism of re-
lease is hypothesised to be different to neuronal ACh due to the fact that the majority of 
non-neuronal cells cannot generate action potentials or open voltage regulated calcium 
channels which trigger exocytosis (Wessler et al., 2001) . Indeed, in the placental model 
of non-neuronal ACh release it has been found that ACh leaves cells via organic cation 
transporters (OCTs) (Wessler et al., 2001). OCTs are members of the solute carrier fam-
ily of transporters responsible for the influx and efflux of organic cations, such as ACh, 
across cell membranes. There are 37 known members of the OCT family and they are 
ubiquitously expressed in humans, although the evidence, from the placental model of 
non-neuronal ACh, suggests that OCT1 and OCT3 are the favoured subtype for in-
volvement in ACh release (Wessler et al., 2001). Unlike a typical hormone, ACh is rap-
idly hydrolyzed upon its release predominantly by the enzyme acetylcholinesterase 
(AChE), with a small contribution from butyrylcholinesterase (BChE), into choline and 
acetate (Wessler and Kirkpatrick, 2008), therefore limiting the efficacies of ACh to cells 
in close proximity to its site of synthesis and release (Figure 1). 
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Figure 1 
Diagram demonstrating the proposed mechanism of acetylcholine synthesis, re-
lease, action and breakdown at a cholinergic nerve terminal. ACh = acetylcholine, 
ChAT = choline acetyltransferase, CHT1 = high-affinity choline transporter-1, VAChT 
= vesicular ACh transporter, AChE = acetylcholinesterase, BChE = butyrylcholinester-
ase, mAChR = muscarinic receptors and nAChR = nicotinic receptors. (Adapted from 
(Kummer et al., 2008)).  
 
 
1.6 Acetylcholine Receptors 
 
Upon release, ACh acts on either muscarinic or nicotinic receptors (mAChR and nA-
ChR, respectively). The metabotropic actions of ACh are mediated by activation of the 
muscarinic receptor family. These receptors are seven transmembrane glycoproteins en-
coded by intronless genes; and comprise five distinct subtypes, denoted as muscarinic 
receptor type 1 - 5 (M1 – M5). Activation of mAChRs is relatively slow and depending 
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on the subtypes involved causes alterations in cellular levels of phospholipase C, inosi-
tol trisphosphate, cyclic AMP (cAMP) and free calcium (Ishii and Kurachi, 2006). Up-
on activation, mAChRs couple to heterotrimeric guanine nucleotide binding proteins (G 
proteins) to regulate second messengers and ion channel activities (Wessler and 
Kirkpatrick, 2008).  
 
Nicotinic acetylcholine receptors (nAChRs) on the other hand are classic representatives 
of a large superfamily of ligand gated ion channel proteins. The nAChRs are fast iono-
tropic cationic receptors, which mediate the influx of Na
+
 and Ca
2+
 as well as the efflux 
of K
+
 ions. The increase in intracellular Ca
2+
 that arises from nAChR activation can ac-
tivate calcium sensitive signal transduction protein kinases such as adenylyl cyclase 
(AC), protein kinase A (PKA), protein kinase C (PKC), Ca
2+
 calmodulin dependent pro-
tein kinase (CaMK) and phosphatidylinositol 3-kinase (PI3K). In turn, these phosphory-
late downstream targets, such as extracellular signal regulated mitogen activated protein 
kinase (ERK), which leads to the activation of transcription factors such as the cAMP 
response element-binding protein (CREB) and nuclear factor kappa light chain enhanc-
er of activated B cells (NF-κB). In turn, activation of these transcription factors then 
modulates gene expression and leads to phenotypical changes in the cell. To date, 13 
nAChR subunits have been cloned in humans; seven α like subunits (α2, α3, α4, α5, α6, 
α7, α9 and α10) and 6 non-α subunits (β2, β3, β4, δ, ε and ϒ). The α2 – α6, β2 – β 4, δ, 
ε and ϒ subunits can all form hetero-oligomeric receptors, whereas the α7 and α9 subu-
nits can only form homo-oligomeric receptors. To date however the exact signaling 
mechanism(s) mediating downstream effects of many of the nAChRs are not yet com-
pletely understood (Albuquerque et al., 2009).  
 
 
1.7   The cholinergic system of the periodontium 
 
The influence of neuronally derived ACh on periodontal tissues is currently unknown. 
However, oral epithelial cells have been demonstrated to express components of a func-
tional non-neuronal cholinergic system. Therefore, epithelially derived ACh can act in 
both an autocrine and paracrine manner to regulate periodontal tissue function. The epi-
thelial cells lining the human attached gingiva have been shown to express the ACh 
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synthesising enzyme, ChAT, and two molecular forms of the degrading enzyme, AChE 
(Nguyen et al., 2000). In addition, although the literature is sparse on the subject there is 
pharmacological evidence to show that oral epithelial cells express OCTs (Brayton et 
al., 2002). The demonstration of these components in human oral epithelium is evidence 
that cells of the periodontium can synthesise and release ACh. Indeed, free ACh has 
been detected in oral keratinocyte homogenates and culture supernatants (Grando et al., 
1993) as well as gingival tissue samples (Rajeswari and Satyanarayana, 1990). In addi-
tion, oral keratinocytes and fibroblasts express both nicotinic (nAChR) and muscarinic 
(mAChR) ACh receptors. The α3, α5, α7, α9, β2 and β4 nAChR receptor subunits 
(Nguyen et al., 2000)  and the muscarinic type 2 (M2), type 3 (M3), type 4 (M4) and 
type 5 (M5) receptors (Arredondo et al., 2003) are all expressed in human gingival 
keratinocytes. Furthermore, although the ACh receptor profile of oral fibroblasts has yet 
to be fully elucidated; periodontal ligament fibroblasts are known to express the 
α7nAChR (Wang et al., 2010) and pharmacological studies using arecoline and 
methocramine hemihydrate provide evidence for the expression of muscarinic receptors 
by gingival fibroblasts (Thangjam et al., 2009, Thangjam and Kondaiah, 2009).  
 
Research into the biology of ACh within the periodontium has mainly centred on its 
role in the regulation of oral keratinocyte growth and differentiation. Indeed it has been 
demonstrated that tobacco products act upon nAChRs and can alter cell cycle progres-
sion and lead to squamatisation of oral keratinocytes and squamous cell carcinoma 
(Arredondo et al., 2008a).  Interestingly, alterations to oral keratinocyte cell cycle pro-
gression and differentiation to the squamous cell phenotype was found to coincide with 
increased expression of nAChR subunit (Arredondo et al., 2006, Arredondo et al., 
2008b). Furthermore activation of the nAChRs was shown to play a central role in the 
oral keratinocytes response to tobacco products via an intracellular signalling pathway 
which increased expression and nuclear translocation of both the signal transducer and 
activator of transcription 3 (STAT-3) and NF-κB transcription factors; which play a role 
in the control of expression of genes involved in mediating cell growth and apoptosis 
(Arredondo et al., 2006, Arredondo et al., 2007).  
 
These findings present strong functional evidence for a non-neuronal cholinergic system 
operating within the periodontium. Although to date the research only suggests an im-
portant role for ACh in regulating cellular growth, death and differentiation. Non-
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neuronal ACh is however a multifunctional cytotransmitter involved in numerous cellu-
lar processes including modulating gene expression, cellular proliferation, cytoskeletal 
organization, cell-cell contact (tight and gap junctions, desmosomes), locomotion, mi-
gration, ciliary activity, electrical activity, secretion and absorption. In addition, non-
neuronal ACh also plays a role in the control of unspecific and specific immune func-
tions (Wessler et al., 2003) It is therefore interesting to speculate a similar role for non-
neuronal ACh in the periodontal environment. 
 
 
1.8   The cholinergic anti-inflammatory pathway 
 
Recently the alpha7 nicotinic receptor (α7AChR) has received a great deal of attention 
from immunologists due its crucial role in regulating the ‘cholinergic anti-inflammatory 
pathway’. The discovery of the ‘cholinergic anti-inflammatory pathway’ was a major 
breakthrough and was described as the ‘missing link in neuroimmunomodulation’ 
(Pavlov et al., 2003). The pathway was first postulated after pioneering work by the 
group of Kevin Tracey who demonstrated that systemic, hepatic and splenic Tumour 
Necrosis Factor alpha (TNF-α) production and symptoms of endotoxemia were exacer-
bated in rodents which had undergone a vagotomy and reversed in animals subjected to 
electrical stimulation of the cervical vagal nerve (Borovikova et al., 2000). The pathway 
is initiated by hallmarks of inflammation activating the afferent vagus nerve and relay-
ing information warning of the occurring inflammation to the brain. Subsequent efferent 
vagal nerve activity then leads to an increase in ACh release within the inflamed periph-
eral tissues lying proximal to the nerve. The free ACh then binds to the α7AChRs on 
immune competent cells and regulates localised inflammatory processes. It is therefore 
the efferent arm of the vagal nerve reflex which is actually termed the ‘cholinergic anti-
inflammatory pathway’. The cholinergic anti-inflammatory pathway is therefore im-
portant in ensuring the appropriate degree of immune system activation for the per-
ceived threat (Figure 2).  
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Figure 2 
Diagram demonstrating the basic principles of the ‘cholinergic anti-inflammatory 
pathway’ Cytokines such as those of the TNF and IL-1 family released from inflamed 
tissue activate the sensory (afferent) vagus nerve relaying information of the occurring 
inflammation to the brain. Subsequent (motor) efferent vagal nerve activity then leads to 
ACh release within the inflamed peripheral tissues lying proximal to the nerve. The free 
ACh then binds to the α7AChRs on immune competent cells and down regulates local-
ised inflammation (Adapted from (Pavlov et al., 2003). 
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1.9 The α7nAChR and the cholinergic anti-inflammatory path-
way 
 
The ‘cholinergic anti-inflammatory pathway’ has been the subject of extensive research 
over the last 10 years. Studies have demonstrated that vagus nerve stimulation can at-
tenuate the systemic inflammatory response to endotoxin (Borovikova et al., 2000). Fur-
thermore, studies using α7nAChR-deficient (α7nAChR-/-) animals have demonstrated 
the importance of this receptor in modulating the ‘cholinergic anti-inflammatory path-
way’ and controlling unrestrained inflammation in response to pathogens. For example, 
α7nAChR-/- mice were found to be hypersensitive to bacterial lipopolysaccharide (LPS) 
and exhibited an exaggerated production of pro-inflammatory cytokines such as TNF-α, 
IL-1β and IL-6 (Wang et al., 2003). Indeed, using α-bungarotoxin, an inhibitor of the 
α7nAChR, activation of this receptor was demonstrated to be critical for the suppression 
of TNF-α release in response to LPS in mice (Wang et al., 2003). In addition, α7nAChR-
/-
 mice, upon treatment with LPS or upon infection with Escherichia coli (E. coli), were 
shown to develop more severe lung injury and to have more mortality than correspond-
ing α7nAChR+/+ mice in a model of sepsis induced lung injury (Su et al., 2010).  
 
An anti-inflammatory role for the α7 nAChR in arthritis was suggested using both vagal 
nerve stimulation and cholinergic agonists. Vagal nerve stimulation was shown to sup-
press the development of collagen-induced arthritis (CIA) in a rat model and this coin-
cided with a decrease in serum levels of TNF-α and in turns a reduction in osteoclasts 
within the joint. This suggested an indirect role for cholinergic control of bone destruc-
tion (Zhang et al., 2010). Furthermore, mice that were subjected to a cervical vagotomy 
and induction of arthritis with type II collagen demonstrated that clinical arthritis was 
exacerbated by vagotomy and ameliorated by nicotine administration (Liu et al., 2011, 
van Maanen et al., 2009a). However, in a model of CIA, α7nAChR-/- mice exhibited 
significant increases in incidences and severity of arthritis as well as increased synovial 
inflammation and joint destruction compared to wild type litter mates. This exacerba-
tion was found to coincide with elevated systemic levels of proinflammatory cytokines, 
an enhanced Th1 profile and elevated TNF-α production from spleen cells (van Maanen 
et al., 2010). In contrast, using a similar animal model, the lack of α7nAChR was actu-
ally found to suppress the development of CIA (Westman et al., 2010). However, this 
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study was performed over a 14 day period whilst the previous study was performed over 
a 44 day period which is more representative of the acute phase of the disease. Interest-
ingly though, this second study demonstrated that the α7nAChR plays a role in the adap-
tive immune response, in addition to localised innate immune responses, in arthritis as 
in the α7nAChR-/- animals a decreased T cell content and proliferation was observed in 
both the spleen and lymph nodes (Westman et al., 2010).  
 
 
 
1.10   Pharmacologically targeting the α7nAChR to treat chronic 
inflammatory diseases 
 
Targeting the α7AChR has been the subject of investigation for potential therapeutics to 
treat chronic inflammatory conditions such as, Crohn’s disease, psoriasis, rheumatoid 
arthritis, asthma, sepsis and diabetes (Bencherif et al., 2011). Table 1 shows examples 
from the literature in which α7AChR agonists have shown promise in animal models for 
treating a variety of inflammatory conditions. 
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α7nAChR 
agonist  
Animal 
model 
Inflammatory 
condition Outcome Reference 
          
GTS-21 Mouse  
Endotoxemia 
Sepsis 
Improved survival coinciding 
with decreased serum  
Pavlov et 
al., 2007 
   levels of TNF-α and HMGB1  
     
 Mouse  Pancreatitis 
Lower pancreatic inflammation 
with decreased plasma  
van West-
erloo et 
al., 2006 
   levels of IL-6 and amylase  
     
PNU-
282987 Mouse  
Acute  lung 
injury 
Decreased excess lung water 
and lung vascular  
Su et al., 
2007 
   
permeability with reduced TNF-
α and MIP2 in BAL  
     
AR-R17779 Mouse 
Rheumatoid 
Arthritis 
Ameliorated clinical arthritis 
and reduced synovial inflamma-
tion with a reduction of TNF-α 
levels  
Van 
Maanen et 
al., 2009 
     
     
 Mouse 
Intestinal in-
flammation 
Prevents postoperative ileus 
characterised by reduced   
The FO et 
al., 2007 
   inflammatory cell recruitment   
     
DMPP Mouse Asthma 
Reduced airway inflammation 
with reduced IgE and  
Blanchet 
et al., 
2005 
   number of eosinophils in BAL  
     
TC-7020 Mouse 
Type 2 Diabe-
tes 
Reduced weight gain, glucose 
and glycated hemoglobin  
Marrero et 
al., 2010 
      
levels and lowered plasma lev-
els of TNF-α   
 
Table 1: Specific α7nAChR pharmaceutical agonists investigated in the literature for 
their In vivo therapeutic effects on the pathogenesis of a number of inflammatory condi-
tions. 
 
Indeed, ongoing research has shown that using α7nAChR agonists have been used in 
regulating cytokine responses and thereby in the treatment of excessive inflammation in 
preclinical models of disease. An example of an α7nAChR agonist is GTS-21, this 
compound is tolerated well by human volunteers, and it has been used for mechanistic 
studies and potential therapeutic development (Pavlov, 2008). GTS-21 has been previ-
ously used to counteract deterioration in preclinical studies of Alzheimer’s disease 
(Pavlov et al., 2007).  Moreover, this compound has been used to improve survival in 
murine endotoxemia and severe sepsis. In a study by Pavlov et al., it has been shown 
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that GTS-21 suppresses dose dependently serum TNF and improves survival during le-
thal endotoxemia in mice models treated with endotoxin or subjected to cecal ligation 
and puncture (CLP) (Pavlov et al., 2007). In addition, Van Westerloo et al  have demon-
strated that treatment with GTS-21 significantly reduces pancreatitis severity and in-
flammation in mice (van Westerloo et al., 2006). This was indicated by the downregula-
tion of the plasma amylase and lipase levels which protects against pancreatic tissue 
damage. (van Westerloo et al., 2006). In the same study, GTS-21 has also been shown 
to suppress neutrophil influx into the pancreas and reduces plasma IL-6 levels (van 
Westerloo et al., 2006). 
 
Another example of the α7nAChR agonists used in vivo in previous studies is PNU-
282987, a highly specific α7nAChR agonist. PNU-282987 has been used in an acid-
induced acute lung injury mouse model (Su et al., 2007). This compound was found to 
reduce excess lung water and extravascular plasma equivalents. It also decreased neu-
trophil accumulation in the airspaces, with the downregulation of TNF-α and MIP-2 
levels in the broncho-alveolar lavage (BAL) (Su et al., 2007). In another study by Su et 
al, PNU 282987 has been found to play an important role in suppressing LPS or live E. 
coli- induced acute lung inflammatory injury in mice (Su et al., 2009). Both specific 
α7nAChR agonists have downregulated proinflammatory responses (MIP-2 production) 
and neutrophil migration in the early stage of lung inflammation (Su et al., 2009). 
 
In an arthritis model, mice that were administered nicotine showed inhibited bone deg-
radation and reduced TNF-α expression, while mice that were administered a specific 
α7nAChR agonist (AR-R17779) demonstrated a total amelioration of clinical arthritis 
and significantly reduced synovial inflammation accompanied by a reduction of TNF-α 
levels in both plasma and synovial tissue (van Maanen et al., 2009a). As the agonist 
AR-R17779 could not pass the blood brain barrier the authors hypothesized that its ef-
fects occurred on α7nAChRs proximal to the site of inflammation. Indeed, expression of 
the α7nAChR was later observed on the intimal lining of the synovium and in cultured 
fibroblast-like synoviocytes (FLS) (Waldburger et al., 2008, Westman et al., 2010). 
Moreover, The et al have shown that AR-R17779 abolishes gastric emptying caused by 
surgical intestinal manipulation and it has been found to prevent post-operative ileus 
(The et al., 2007). This compound also downregulated pro-inflammatory cytokine re-
lease from peritoneal macrophages and suppressed NF-κB activation (The et al., 2007). 
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DMPP (1, 1-dimethyl-4-phenylpiperzinium), another nicotinic agonist, was found to 
exhibit anti-inflammatory and bronchopreotective effects through the prevention of air-
way hyper-responsiveness in a mouse model of asthma (Blanchet et al., 2005). Blanchet 
et al. have found that DMPP administration intranasally in the asthma mouse model re-
duced the numbers of lymphocytes and eosinophils in the bronchoalveolar lavage fluid 
and it also reduced the intracellular calcium release triggered by bradykinin (Blanchet et 
al., 2005). 
 
TC-7020 binds to α7nAChR with high affinity and exhibits very poor affinity toward 
other nicotinic subtypes (Mazurov et al., 2011). Oral administration of TC-7020 in a 
mouse model of type 1 diabetes reduced weight gain and food intake; lowered elevated 
glucose and glycated hemoglobin levels and reduced elevated plasma levels of triglycer-
ides and TNF-α (Marrero et al., 2010). These effects were reversed when an α7nAChR 
antagonist (methyllycaconitine) was used, thus confirming the involvement of 
α7nAChR (Marrero et al., 2010). 
 
Indeed, PHA 543613 proved to be a potent, high affinity agonist of α7nAChR. Due to 
its excellent in vitro profile, rapid brain penetration, high oral bioavailability in rats and 
its favorable hERG profile. This highly specific α7nAChR agonist was found to sup-
press MIP-2 production and neutrophil migration in a live E. coli- induced acute lung 
inflammatory injury in mice (Su et al., 2009). In addition, PHA 543613 has demonstrat-
ed efficacy in in vivo models for treatment of Alzheimer’s disease and Schizophrenia 
(Wishka et al., 2006).  
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1.11   Pharmacologically targeting the α7nAChR of specific cells 
modulates their immune capacity 
 
Numerous in vitro studies have demonstrated that activation of the α7nAChR can inhib-
it the immune response of cells to a variety of stimuli (Table 2). 
 
α7nAChR 
agonist  Cell Type Stimulus Outcome Reference 
          
Nicotine      Epithelial TNF-α, LPS 
Inhibited IL-8 and 
TNF-α  expression 
Li et al., 
2011 
     
     
GTS-21   Macrophages  LPS 
Inhibited IL-1β, 
HMGB1 and TNF-α  
expression 
Rosa-Ballina 
et al., 2009 
     
     
Choline   Macrophages LPS 
Inhibited TNF-α ex-
pression 
Chernyavsky 
et al., 2010 
     
     
AR-R17779 Synoviocytes TNF-α 
Inhibited Il-8 and Il-6 
expression 
Van Maanen 
et al., 2009 
     
     
PHA 543613 
HCl Neurons 
Intestinal in-
flammation 
Inhibited HMGB1 ex-
pression 
Wang et al., 
2012 
   
inflammatory cell re-
cruitment   
     
 
Table 2: Targeting the α7nAChR on individual cell types inhibits their proinflammatory 
responses to stimuli.  
  
 
Indeed, AR-R17779 has been shown to significantly downregulate the expression of IL-
6 and several cytokines, including CXCL8 (IL-8) by TNF-α stimulated Fibroblast-like 
synoviocuyes (FLS) (van Maanen et al., 2010). Furthermore, the pharmacological 
α7nAChR agonist 3-(2, 4-dimethoxybenzylidene) anabesine (GTS-21) inhibited the 
Toll-like receptor mediated expression of TNF-α and IL-6 from macrophages (Rosas-
Ballina and Tracey, 2009). In airway epithelial cells of cystic fibrosis patients, the acti-
vation of the α7nAChR was shown to inhibit Toll like receptor 2 (TLR-2) mediated IL-
8 expression (Greene et al., 2010). In addition, activation of the α7nAChR was demon-
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strated to inhibit TNF-α induced IL-8 expression in human colon epithelial cells 
(Summers et al., 2003) and nicotine was also shown to reduce TNF-α expression in 
HBE16 airway epithelial cells, mainly through the α7nAChR influencing the NF-KB 
pathway (Li et al., 2011b). Chernyavsky et al have shown that the nicotinic agonist Epi-
batidine was able to decrease TNF-α in LPS- stimulated macrophage-like U937 cells 
(Chernyavsky et al., 2010). Moreover, electropuncture pretreatment affected neuronal 
apoptosis in a recent study by Wang et al, which was reduced by applying PHA 543613 
HCl through the inhibition of HMGB1 release into the culture medium (Wang et al., 
2012). 
 
Indeed, in vitro studies in macrophages have provided vital clues as to the α7nAChR 
mediated signaling pathways which result in an anti-inflammatory phenotype. Macro-
phages/monocytes have also been shown to express the α7nAChR (Toyabe et al., 1997) 
and its activation demonstrated to mediate signaling pathways leading to down regulat-
ed NF-κB nuclear translocation and the suppression of transcription of proinflammatory 
cytokines. Indeed, treatment of LPS activated human peripheral monocytes with low 
doses of nicotine caused inhibition of TNF-α and macrophage inflammatory protein 1 
alpha (MIP-1α) expression. These effects were mediated through the α7nAChR which 
led to the suppressed phosphorylation of the Inhibitor of kappa B α (IκBα) and in turn 
inhibited the transcriptional activity of NF-κB (Yoshikawa et al., 2006) (Figure 3). Fur-
thermore, studies in peritoneal macrophages showed that activation of the α7nAChR 
can also stimulate the JAK-2/STAT-3 pathway both in vitro and in vivo. Activation of 
the STAT-3 cascade by the ligation of nicotine to the α7nAChR led to inhibition of pro-
inflammatory cytokine release as STAT-3 is a negative regulator of the inflammatory 
response (de Jonge et al., 2005) (Figure 3). Interestingly, STAT-3 activation is required 
for the anti-inflammatory action of IL-10 via the IL-10 receptor and studies have shown 
that activation of the α7nAChR may only induce specific down regulation of pro-
inflammatory cytokines as it did not prevent the constitutive release of the anti-
inflammatory; IL-10 (de Jonge et al., 2005). 
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Figure 3 
Diagram demonstrating the two major mechanisms by which activation of the 
α7nAChR can inhibit expression and release of proinflammatory cytokines by 
macrophages. Activation of the α7nAChR has been demonstrated to inhibit the expres-
sion of proinflammatory cytokines. Activation of the α7nAChR inhibits the phosphory-
lation of Inhibitor of Kappa B (IκB) by the Inhibitor of Kappa B kinase (IKK). This in 
turn inhibits the dissociation of IκB from the active p50/p65 NF-κB complex and pre-
vents translocation of the active NF-κB transcription factor into the nucleus and there-
fore inhibits expression of proinflammatory cytokines. Activation of the α7nAChR has 
also been shown to lead to the formation of a heterodimeric protein complex with phos-
phorylated Janus Kinase 2 (Jak2). The active JAK2 then activates the signal transducer 
and activator of transcription 3 (STAT3). The active STAT3 molecule can then translo-
cate to the nucleus where it acts as a negative regulator of proinflammatory cytokine 
expression. 
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1.12   Cholinergic regulation of the periodontal immune re-
sponse? 
 
Evidence suggests that ACh and the α7nAChR can play a key role in the pathogenesis 
of chronic inflammatory diseases such as rheumatoid arthritis. It is known that there are 
remarkable similarities in the pathogenesis of periodontal disease and rheumatoid arthri-
tis; in particular with regard to a poorly modulated inflammatory response resulting in 
tissue injury and bone loss. Therefore it is interesting to speculate that similar mecha-
nisms may operate within the periodontium to prevent an unrestrained inflammatory 
response.  
 
To date, the influence of the vagal nerve on the oral cavity is a matter of debate. Indeed 
whether the vagal nerve can regulate the periodontal immune response is unknown at 
present. Undoubtedly, the vagal nerve plays an important role as a sensory and nocicep-
tive system to communicate the activation state of the immune system to the brain. 
However, it is still questionable whether the anti-inflammatory effect on immune cells 
is mediated directly by vagally released neuronal ACh (Nance and Sanders, 2007). In-
deed, it has to be considered that the enzyme responsible for the breakdown of ACh, 
AChE, is extremely effective and stops neuronal ACh from migrating far from its 
source. Therefore, for the mechanism to be effective the immune cells need to be in 
close proximity to the source of neuronal ACh. Although some immune cells do show 
close membrane apposition with neuronal elements, for example, in the area postrema 
(Goehler et al., 2006), this is not always the case. Indeed there is little evidence to sug-
gest that there is close apposition of immune cells with neuronal elements within the 
periodontium. Therefore, the question remains as to how a vagally mediated efferent 
response on immune cells is migrated through periodontal tissue which are not in close 
proximity to nerve fibers? Indeed, although a functional relationship between inflamma-
tory disease pathogenesis and the ‘cholinergic anti-inflammatory pathway’ was con-
firmed when it was discovered that a decrease in vagal nerve tone (reflecting parasym-
pathetic activity) occurs in patients with rheumatoid arthritis (Stojanovich et al., 2007). 
The actual response of the isolated inflammatory cells from these patients to cholinergic 
agonists ex vivo was found to be mediated by mechanisms that were independent of va-
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gus nerve activity (Bruchfeld et al., 2010). The evidence therefore suggested that non-
neuronally derived ACh played a role in regulating localised inflammation.  
 
As described previously (1.6), evidence suggests that functional non-neuronal choliner-
gic systems operate within the periodontium. Initial studies have demonstrated a role for 
ACh in oral keratinocyte growth and differentiation (Arredondo et al., 2006, Arredondo 
et al., 2008). The α7nAChR is widely expressed by cell types found in the periodontium 
including oral epithelial cells. At present however, it is unknown whether the receptor 
plays a role in modulating the immune response of these cells to oral pathogens. How-
ever, based on substantial evidence from other cell types (section 1.11), it is interesting 
to hypothesise that pharmacologically targeting the α7nAChR on oral keratinocytes 
modulates their immune response to periodontal pathogens in vitro. 
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1.13   Objectives:  
 
The aim of this project was to investigate the effects of carbachol and the α7nAChR ag-
onist, PHA543613 HCl, on IL-8 expression by oral keratinocytes in response to the per-
iodontal pathogen; P. gingivalis. Evidence in the scientific literature shows that the 
α7nAChR can regulate the inflammatory response to pathogens of many cells; including 
immune-competent epithelial cells such as those of the airway (Li et al., 2011b) and co-
lon (Summers et al., 2003). To date, however, there is no direct evidence for a role of 
α7nAChR in regulating the innate immune response of oral epithelial cells. Existing lit-
erature indicates that oral keratinocytes express the α7nAChR (Nguyen et al., 2000, 
Wang et al., 2010); however its role in the innate immune response against oral patho-
gens had not been investigated. Interestingly, in various models of sepsis activation of 
the α7nAChR has been demonstrated to inhibit localized neutrophil recruitment (Saeed 
et al., 2005). Neutrophil recruitment is one of the key hallmarks of the early stages of 
periodontal disease pathogenesis. In addition, the chemokine, IL-8, is known to be an 
important molecule in promoting neutrophil chemotaxis into the periodontal tissues. 
The α7nAChR has been demonstrated to modulate the expression of TNF-α induced IL8 
expression in human colon epithelial cells in response to pathogen (Summers et al., 
2003).  Therefore it is interesting to speculate that the α7nAChR on oral keratinocytes 
may modulate their ability to express and release IL-8 and therefore, by modulating 
neutrophil chemotaxis, play a role in the pathogenesis of periodontal disease.  
 
The specific objectives of the project are: 
 
1- To confirm the presence of α7nAChRs on oral keratinocytes and the 
OKF6-TERT2 oral keratinocyte cell line to determine their suitability as a 
model for our in vitro studies. 
 
2- To investigate of the direct effects of Carbachol (an ACh mimic) on IL-8 
expression by OKF6-TERT2 cells in the presence or absence of dead P. 
gingivalis. 
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3- To determine the effects of a specific α7nAChR agonist (PHA543613 
HCl) on IL-8 expression by OKF6-TERT2 cells in response to a live P. 
gingivalis biofilm. 
 
4- To determine the influence of α7nAChR activation on the NF-κB signal-
ing pathway, and therefore control of IL-8 expression, in OKF6-TERT2 
cells. 
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                           2   Materials and methods 
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2.1 Tissue samples 
 
Gingival tissues (n = 15) were obtained from patients with written consent, undergoing 
open flap debridement in the Unit of Periodontics at Glasgow Dental Hospital. Ethical 
review and approval was provided by the West of Scotland Research Ethics Committee. 
Patients undergoing open flap debridement had probing pocket depths of ≥ 6.0 mm, 
with clinical attachment loss of ≥ 4.0 mm, which persisted after non-surgical treatment. 
Patient age ranged from 38 - 64 years with a mean age of 47 years. Healthy control tis-
sues were obtained from patients with clinically healthy periodontal tissues undergoing 
surgical crown-lengthening procedures (n=10). The tissue samples were immediately 
submerged in RNAlater (Qiagen, UK) and stored at - 80 
o
C.  
 
 
 
2.2 RNA extraction from periodontal tissue samples and prepa-
ration of cDNA 
 
Extraction and purification of total RNA from periodontal tissues samples was carried 
out using the RNeasy® Fibrous Tissue Kit (Qiagen, UK). In brief, a maximum of 30 mg 
of periodontal tissue was placed in an eppendorf tube containing 300 µl of 1 % ß-
Mercaptoethanol in Buffer RLT (Qiagen, UK). The mixture was then homogenized us-
ing a disposable rotor-stator tissue homogenizer for 20 – 40 seconds. Then, 590 µl of 
RNase-free water and 10 µl of Proteinase K (Qiagen, UK) were added to the homoge-
nous lysate and the mixture was incubated for 10 minutes at 55 
o
C in a heat block. The 
homogenate was then centrifuged at 11000 rpm for 3 minutes at room temperature to 
remove the tissue remnant. Next, the supernatant (700 – 900 µl) was transferred into a 
1.5 ml microcentrifuge tube, followed by addition of an equal volume of ethanol (96 – 
100 %). 
The mixture was gently mixed by pipetting up and down before being transferred onto 
an RNeasy spin column (Qiagen, UK) placed in a 2 ml collection tube and centrifuged 
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for 15 seconds at 11000 rpm. The flow through was then discarded and the membrane 
column was washed with 350 µl Buffer RW1 (Qiagen, UK) and centrifuged for 15 sec-
onds at 11000 rpm. The flow through was again discarded and on column DNase diges-
tion was performed by incubating the membrane for 15 minutes at room temperature 
using a mixture of 10 μl DNase I stock solution (Qiagen, UK) and 70 μl Buffer RDD 
(Qiagen, UK). Afterwards, the column was washed again using Buffer RW1 (Qiagen, 
UK). Next, the column was washed twice with 500 µl Buffer RPE (Qiagen, UK). Final-
ly, RNase-free water (30 µl) was used to elute the RNA from the column by centrifuga-
tion at 11000 rpm for 1 min. This final procedure was repeated to get a final elution 
volume of 60 µl. A NanoDrop® 1000 spectrophotometer (Thermo Scientific, UK) was 
used to assess the quantity and quality of the extracted total RNA. 
The cDNA was then synthesised using the high capacity RNA to cDNA kit (Applied 
biosystems, UK). The mastermix contains random hexamers, dNTP mix (dATP, dGTP, 
dCTP and dTTP), RNase out, MgCl2 and reverse transcriptase. A NanoDrop 1000 spec-
trophotometer (Thermo Scientific, UK) was used to assess the quantity and quality of 
the total RNA. After isolation, mRNA was reverse transcribed to cDNA using the High 
Capacity RNA-to-cDNA Master Mix (Applied Biosystem, UK). Each reverse transcrip-
tion reaction consisted of 1000 ng RNA and 4 µl of 5 X complete master mix and made 
up to a 20 l total reaction volume with RNase free water. Reverse transcription was 
performed on a Mycycler Thermal Cycler (Biorad, UK) under the following conditions: 
5 minutes at 25
 o
C, 30 minutes at 42
 o
C and 5 minutes at 85
 o
C.  The cDNA was stored 
at 4 
o
C for immediate analysis or -20 
o
C for long term storage and later analysis. 
 
2.3 TaqMan® Real Time PCR analysis 
Real time PCR was carried out using 2 X TaqMan
®
 Gene Expression Master Mix (Ap-
plied Biosystems, UK) and 20 X TaqMan
®
 Gene Expression Assay mix for the 
α7nAChR (Hs 01063373_m1) (Applied Biosystems, UK). Expression levels of the 
α7nAChR were corrected for the expression of a house keeping gene; RNA polymerase 
II; POL2RA (Hs_00172187_m1) (Applied Biosystems, UK). Each 20 µl real time PCR 
reaction consisted of: 10 µl of master mix, 1 µl of gene expression assay mix, 7 µl of 
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RNase-free water, and 2 µl of cDNA. Analysis of samples was performed in duplicate 
in a 96 well plate format on a MX3000P
TM
 real time PCR machine (Stratagene, UK) 
under the following conditions: 50 C for 2 minutes, 95 C for 10 minutes, followed by 
40 cycles of 95 C for 15 seconds and 60 C for 1 minute. The data was analyzed using 
MxPro-Mx3000P software, version 4.10 (Stratagene, UK). Relative expression of 
α7nAChR mRNA was calculated using the 2-CT method (Schmittgen and Livak, 2008). 
Briefly, the 2
-CT 
value is the CT value of the gene of interest (in this case the α7nAChR) 
for a sample normalized against the CT value for the endogenous housekeeping gene (in 
this case POL2RA).  
 
2.4 Cell culture 
OKF6-TERT2 (OKF6) epithelial cells are an immortalized normal oral epithelial cell 
line originated from keratinocyte cells of the oral mucosa (a kind gift of Dr. James 
Rheinwald, Brigham and Women’s Hospital, Boston, USA). OKF6 cells were main-
tained at 37 
o
C in microaerophilic conditions (5% CO2) in keratinocyte-serum-free me-
dium (K-SFM, Invitrogen, UK) containing 2 mM L-glutamine, 25 µg/l bovine pituitary 
extract (BPE) (Invitrogen, UK), 0.2 ng/ml human epithelial growth factor (EGF) (Invi-
trogen, UK), 100 IU/ml  Penicillin (Sigma-Aldrich, UK), 100 mg/ml Streptomycin 
(Sigma-Aldrich, UK) and 0.2 M calcium chloride in cell culture flasks (Corning Incor-
porated, USA). The growth media was changed at two-to-three day intervals and cells 
were passaged when they reached 70 – 80 % confluence.  
To passage, cells were first washed with PBS (Sigma, UK). Cells were then removed by 
addition of 0.05% trypsin and incubation at 37 
o
C for around 2 minutes (cells were 
checked under the microscope to ensure they had completely detached). Dulbecco’s 
Modified Eagles Medium (DMEM) with 10% Foetal Calf Serum (FCS) (Sigma, UK) 
was then added to the supernatant to inactivate the trypsin. The cells were then centri-
fuged for 5 minutes at 1000 RPM and washed twice in Hanks Solution (Sigma, UK). 
Cells were the counted using Trypan blue (Sigma, UK) on a haemocytometer and either 
resuspended in Defined Serum-Free Medium (DKFSM) to be used for experiments or  
put back in flasks containing K-SFM at a density 1x 10
5
 cells/ml  for continuous cul-
ture.   
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2.5 Preparation of Porphyromonas gingivalis monospecies bio-
film 
 
The monospecies biofilms were prepared using Porphyromonas gingivalis (P. gingi-
valis) ATCC 33277. The bacteria were maintained at 37 °C on fastidious anaerobic agar 
(FAA: Oxoid, Cambridge, UK) with 5% defibrinated horse blood (E&O laboratories, 
UK), in an anaerobic chamber (Don Whitley Scientific Limited, UK) set at 85 % N2, 
10% CO2 and 5% H2 for 3 days. A loopfull of cultured bacteria was then used to inocu-
late a flask of Schaedler anaerobe broth (Oxoid,, UK) which was then cultured for 2 
days at 37 °C in the anaerobic chamber (Don Whitley Scientific Limited, UK).  The 
broth was then centrifuged at 3000 rpm for 5 min to pellet the bacteria that were then 
washed with PBS (pH 7.4). The bacteria were then resuspended in PBS and diluted to 
an OD550 of 0.2 in a colorimeter (Fisher Scientific, UK) to obtain approximately 1 x 10
8 
CFU/ml. The live bacterial counts were confirmed by Miles and Misra plate counting 
method. The Miles and Misra method is a technique used in microbiology to determine 
the number of colony forming units (CFU) in a bacterial suspension. Briefly, 5 x 20 µL 
drops of bacterial suspension were pipetted onto a specific agar plates and incubated 
under the appropriate culture conditions. After incubation, the number of viable colo-
nies of microorganisms is then determined by counting (Miles et al., 1938). P. gingi-
valis suspensions were then standardized to a concentration of 1 x 10
7
 CFU/ml in artifi-
cial saliva (0.25% porcine stomach mucins, 0.35% sodium chloride, 0.02% potassium 
chloride, 0.02% calcium chloride dehydrate, 0.2% yeast extract, 0.1% lab lemco pow-
der, 0.5% proteose peptone and 0.05% urea). 500 µl of standardized P. gingivalis was 
then cultured on 13 mm diameter cell culture treated Thermanox
® 
plastic coverslips 
(NUNC, UK), placed in 24 well cell culture plates (Corning, UK). The cultures were 
then incubated at 37 °C in an anaerobic environment for 4 days. Every 24 h the spent 
artificial saliva was replaced with a fresh 500 µl aliquot of artificial saliva. After 4 days 
of incubation, the artificial saliva was removed and the biofilms were stored at -80 °C to 
use in cell stimulation experiments. 
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2.6 Preparation of dead Porphyromonas gingivalis  
 
P. gingivalis ATCC 33277 was cultured as described previous (2.5). The bacteria were 
resuspended in PBS and diluted to an OD550 of 0.2 in a colorimeter (Fisher Scientific, 
UK) to obtain approximately 1 x 10
8 
CFU/ml. The bacterial suspension was then heat 
killed by incubation at 56 °C for 30 minutes. 
 
 
2.7 Cell stimulation experiments 
 
Oral keratinocytes were prepared by seeding replicate wells of 24 well tissue culture 
plates with 1 x 10
5
 cells/ml and incubating in a humidified atmosphere at 37 
o
C and 5 % 
CO2 overnight. To prepare the P. gingivalis biofilms; the frozen biofilms (as described 
in 2.5) were thawed in 500 µl of artificial saliva in an anaerobic chamber for 24 h. On 
the day of the cell stimulation experiments, the coverslips containing the biofilms were 
washed 3 times in sterile PBS and then attached to 24 well Millicell
®
 Cell Culture In-
serts (Millipore, UK) using sterile Vaseline. To stimulate the previously prepared oral 
keratinocyte cultures the insert, with biofilm grown on a Thermonex
® 
coverslip at-
tached, was suspended above the cell mono-layers leaving a gap of approximately 0.5 
mm. This gap represents the gingival sulcus, which is the space existing between the 
tooth surface and the surrounding gingival tissues. Therefore, cell growth and function 
more closely mimic the in vivo environment.  To determine the effects of Carbachol 
(Tocris, UK) and PHA 543613 hydrochloride (Tocris, UK) on the P. gingivalis biofilm 
induced IL-8 expresssion by oral keratinocytes; to some wells various concentrations of 
these compounds were added to the oral keratinocyte cultures 30 min prior to the addi-
tion of the P. gingivalis biofilm. In addition, some wells were just subjected to incuba-
tion with the compounds alone (without biofilm) to ensure they had no effect on IL-8 
expression in isolation. For control purposes some wells were just subjected to a change 
of media (unstimulated and in the absence of any compound). After incubation for 4 and 
24 h the supernatant from each well was removed and stored at -20 
o
C for later analysis 
of IL-8 protein release by ELISA. The remaining adherent cells were then lysed with 
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RLT lysis buffer (Qiagen, UK) and the lysate stored at -80 
o
C for later RNA isolation. 
All in vitro experiments were repeated three times in duplicate wells on different day. 
 
 
2.8 RNA extraction from in vitro cultured cells and cDNA prepa-
ration 
 
Total RNA was extracted from cell cultures using an RNeasy kit (Qiagen, UK), using 
on column DNA digestion with the RNase-free DNase set (Qiagen, UK). Firstly the 
stimulated cells in the 24-well plate were lysed using 350 µl Buffer RLT (Qiagen, UK) 
and 1 % ß-Mercaptoethanol. Then, to the lysed cells, equal volume of ethanol (96 – 100 
%) was added. 
 
The mixture was gently mixed by pipetting up and down before being transferred onto 
an RNeasy spin column (Qiagen, UK) placed in a 2 ml collection tube and centrifuged 
for 15 seconds at 11000 rpm. The flow through was then discarded and the membrane 
column was washed with 350 µl Buffer RW1 (Qiagen, UK) and centrifuged for 15 sec-
onds at 11000 rpm. The flow through was again discarded and on column DNase diges-
tion was performed by incubating the membrane for 15 minutes at room temperature 
using a mixture of 10 μl DNase I stock solution (Qiagen, UK) and 70 μl Buffer RDD 
(Qiagen, UK). Afterwards, the column was washed again using Buffer RW1 (Qiagen, 
UK). Next, the column was washed twice with 500 µl Buffer RPE (Qiagen, UK).  
Finally, RNase-free water (30 µl) was used to elute the RNA from the column by cen-
trifugation at 11000 rpm for 1 min. This final procedure was repeated to get a final elu-
tion volume of 60 µl. A NanoDrop® 1000 spectrophotometer (Thermo Scientific, UK) 
was used to assess the quantity and quality of the extracted total RNA. 
 
 
2.9 Polymerase chain reaction (PCR) 
 
PCR was performed using ReddyMix
TM
 (Thermo Scientific, UK) containing 1.25 units 
of Thermoprime Plus DNA Polymerase, 75 mM of Tris-HCL (pH 8.8 at 25
 o
C), 20 mM 
(NH4)2SO4, 1.5 mM MgCl2, 0.01% (v/v) Tween 20, 0.2 mM each of dATP, dCTP, 
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dGTP, and dTTP and a precipitant and red dye for electrophoresis. Each PCR was per-
formed in a 25 µl reaction volume containing 22.5 µl master mix with 0.5 µl of 100 μM 
of both forward and reverse primers and either cDNA or water as a negative control. 
The PCR was performed on a Mycycler Thermal Cycler (Biorad, UK) under the follow-
ing conditions: 94 °C for 2 min, followed by 45 cycles of 95 °C for 25 sec, 60 
o
C for 35 
sec and 72 °C for 65 sec followed by a final extension at 72 °C for 5 min.  The primer 
sequences used for the α7nAChR (5’ – 3’) were as follows: Fwd = GCA GGA GGC 
AGA TAT CAG T and Rvs = TGA GGC CAT AGT AGA GCG T. PCR products were 
subjected to electrophoresis at 110 volts for 45 minutes on a 2% agarose Tris borate gel 
containing ethidium bromide at 0.5 μg/ml and analysed using the Gel DocTM XR Imag-
ing System (Bio-Rad Laboratories, UK) with Quantity One Software Version 4.6.7 
(Bio-Rad Laboratories, UK). 
 
 
2.10 SYBR® Green Real Time-PCR analysis 
 
The cDNA obtained from the in vitro cultured cells was analysed for IL-8 expression 
using Quantitative PCR with SYBR Green Real Time PCR technology. The reactions 
consisted of 12.5 µl of SYBR Green (Invitrogen, UK), 0.5 μl of each of the following 
primers (5’ – 3’), GAPDH: Fwd: CAAGGCTGAGAACGGAAG and Rvs: 
GGTGGTGAAGACGCCAGT or IL-8: Fwd: CAGAGACAGCAGAGCACACAA and 
Rvs: TTAGCACTCCTTGGCAAAAC, 9 μl H2O and 2.5 μl cDNA (to make a total vol-
ume of 25 μl). The real time PCR was performed on a MX3000PTM real time PCR ma-
chine (Stratagene, UK) under the following conditions: 94 °C for 10 minutes, followed 
by 40 cycles of 94 °C for 30 seconds, 60 °C for 60 seconds and 72 °C for 1 minute; then 
4 °C as a final hold. Relative expression of IL-8 was calculated using the 2
- CT
 method 
(Livak & Schmittgan, 2001). Briefly, the 2
-CT 
value for each unknown was calculated 
as described 2.3. The 2
-ΔΔCT
 was then calculated as follows: 
2
-ΔΔCT
 = 2
-ΔCT
 of treated sample - 2
-ΔCT
 of untreated control  
 
The method allows you to determine the relative increase (or decrease) in expression 
(Fold induction) of the gene of interest (IL-8) in cells which are stimulated (P. gingi-
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valis ± carbachol or PHA543613 HCl) by comparison with the unstimulated control at 
each time point.  
 
 
2.11 Enzyme-linked immunosorbent assay (ELISA) 
 
Interleukin 8 (IL-8) concentrations in supernatants from stimulated cells were deter-
mined using an ELISA kit as per manufacturer’s instructions (Invitrogen, UK). Briefly, 
monoclonal antibodies specific for IL-8 were pre-coated onto MaxiSorp F96 Immuno-
Plates (NUNC, UK) and incubated overnight at 4 °C. The following day the 96-well 
plate was then blocked with blocking buffer for 2 hours at room temperature. The 
blocking buffer was phosphate buffered saline (PBS) with 0.5 % (w/v) Bovine Serum 
Albumin (BSA) (Sigma Aldrich, UK) and 0.1 % (v/v) Tween 20 (Sigma-Aldrich, UK) 
and tapped dry on absorbent paper to remove excess liquids. 100 µl of standards and 
samples were pipetted into each well in duplicate along with 50 µl of working detection 
antibody and the plates were then incubated for two hours at room temperature with 
continual shaking. The wells were then washed five times using wash buffer and 100 µl 
of streptavidin-HRP added into each well and plates incubated for 30 minutes with con-
tinual shaking. The wells were then aspirated five times using wash buffer and 100 µl of 
TMB (3, 3’, 5, 5’-tetra-methylbenzidine) substrate (R&D Systems, UK) was added to 
each well and the plates were incubated for a further 30 minutes with continual shaking. 
Colour development was stopped using 1 M HCl.  The intensity of the colour was read 
at both 650 nm and 450 nm using a Fluostar Omega
® 
microplate reader (BMG Labtech, 
Germany).  Data analysis was done using BMG Analysis Software (BMG Labtech, 
Germany).   
 
 
2.12 Cytotoxicity assay 
 
CytoTox-ONE
TM 
Homogenous Membrane Integrity Assay (Promega, UK) was used to 
measure OKF6 cell viability in the presence of PHA 543613 hydrochloride and car-
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bachol. The assay measures the release of lactate dehydrogenase (LDH) from cells with 
a damaged membrane. PHA 543613 hydrochloride on its own in different concentra-
tions (0.1 nM, 1 nM, 10 nM, 100 nM, 1000 Nm, 10000 nM) or Carbachol in concentra-
tions (1 µM, 10 µM, 100 µM and 1000 µM) were added to the appropriate wells in du-
plicate and the cells were incubated for 4 and 24 hrs. Control wells contained only me-
dia. A volume of CytoTox-ONE™ Reagent equal to the volume of cell culture medium 
present in each well was added and the plate then shaken for 30 seconds. The plate was 
then incubated at 22 °C for 10 minutes and fluorescence determined with an excitation 
wavelength of 560 nm and an emission wavelength of 590 nm. The results were calcu-
lated as follows: First, the average fluorescence values of the culture medium back-
ground were subtracted from all fluorescence values of the experimental wells. Then, 
the average fluorescence values from experimental maximum LDH release, and culture 
medium background were used to calculate the percent cytotoxicity as follows: 
 
Percent cytotoxicity=   100     x          (Experimental - Culture Medium Background) 
                                                 (Maximum LDH release - Culture Medium Background) 
 
The data were represented as a percentage of viability (100-cytotoxicity percentage). 
 
 
2.13 Fast Activated Cell-based ELISA (FACETM) NF-κB p65 profil-
er Assay: 
 
Fast Activated Cell-based ELISA (FACE) NFĸB p65 Profiler Kits are designed spe-
cifically to quantify levels of activated (phosphorylated) forms of the NF-ĸB p65 subu-
nit and/or total NF-ĸB p65 subunit. The antibodies used in this FACE kit were specific 
for total (regardless of phosphorylation state) NF-κB p65 subunit; Serine 468 phosphor-
ylated NF-κB p65 subunit and the Serine 536 phosphorylated subunit. The kit can be 
used to determine the levels of the different forms of the NF-κB p65 subunit relative to 
cell number (cell number corrected). The cell number corrected levels of both the Serine 
468 phosphorylated and the Serine 536 phosphorylated NF-κB p65 subunit were then 
calculated as a percentage of the total cell number corrected NF-κB p65 subunit levels 
as advised by the manufacturer’s protocol. 
51 
 
 
OKF6-TERT2 cells were seeded into 96 well plates at a density of 1 x 10
5
 cells/ml and 
left to adhere overnight in a humidified atmosphere with 5 % CO2 at 37 
o
C. The follow-
ing day, cells were stimulated for 30 minutes with either PHA 543613 hydrochloride 
alone (Tocris, UK), dead P. gingivalis alone (200 cells per OKF6-TERT2 cell equiva-
lent), or dead P. gingivalis in the presence of PHA 543613 hydrochloride (Tocris, UK). 
Supernatants were then discarded and the cells were fixed with 100 μl of 4% formalde-
hyde for 20 minutes. The cells were then washed 3 times with 200 μl wash buffer (0.1% 
Triton X-100 in PBS) followed by a 20 minute incubation with 100 μl Quenching Buff-
er (w Buffer containing 1% H2O2 and 0.1% Azide) at room temperature. After quench-
ing cells were again washed 2 times and 100 μl Antibody Blocking Buffer (supplied by 
the manufacturer) was added to each well and the plate incubated for 1 h at room tem-
perature. Cells were then washed twice as previous, and 40 μl of diluted primary ant i-
body was added to the cells (The supplied primary antibodies are Phospho-NF-κB p65 
antibodies (S468 and S536), and Total- NF-κB p65 antibody, diluted 1/500 in Antibody 
Dilution Buffer (supplied by the manufacturer) (for negative control wells, only Anti-
body Dilution buffer was added). Plates were then sealed and left overnight at 4 °C. The 
following day, the cells were again washed 3 times and incubated for 1 hour with 100 μl 
of diluted secondary antibody (HRP-conjugated anti-rabbit IgG; diluted 1/2000 in Anti-
body Dilution Buffer). Cells were then washed with wash Buffer 3 times and 200 μl of 
PBS twice, followed by the addition of 100 μl of developing solution (supplied by the 
manufacturer) for 2 - 20 minutes. The absorbance of each well was then measured at 
450 nm with a reference wavelength of 655 nm using a Fluostar Omega® microplate 
reader (BMG Labtech, Germany). Data analysis was done using BMG Analysis Soft-
ware (BMG Labtech, Germany).  
    
To determine whether any differences observed in activated NF-κB p65 or total NF-κB 
p65 were due to differences in cell number after the plate was read a crystal violet assay 
was performed as follows. The cells were washed twice with Buffer and then twice with 
PBS and then 100 μl of Crystal Violet solution was added to each well and the plate in-
cubated for 30 minutes. After incubation the cells were washed again 3 times with PBS 
and then 100 μl of 1% SDS solution was added to each well and the plate  incubated  for 
1 hour at room temperature. Finally, the absorbance was read again at 595 nm. The 
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measured OD450 readings are corrected for cell number by dividing the OD450 for a giv-
en well by the OD595 reading for that well. Then the percentage of the total was calcu-
lated as follows: 
 
Percentage of the total = 100   x   Phosphorylated NF-κB p65 subunit levels 
                                                      Total NF-κB p65 subunit levels 
 
 
 
2.14 Statistical analysis 
 
All experiments were performed in duplicate on three separate occasions. For graphical 
purposes data is expressed mean ±standard deviation (SD) of the three experiments.  
 
Statistical analysis of real-time PCR, ELISA and cytotoxicity was performed using 
Graph Pad Prism Version 5 (San Diego, CA, USA). Statistical analysis of the NF-κB 
assays was performed using SPSS (IBM, Chicago, USA). 
 
Tissue α7nAChR real time PCR data and real time PCR data investigating changes in 
IL-8 mRNA expression in cultured OKF6-TERT2 cells were analysed by performing a 
Levene’s test on the variance of the natural log transformed  2-∆CT values followed by an 
independent t-test to compare two means (significance was set at P<0.05).  
Statistical analysis of ELISA and cytotoxicity experimental data was conducted by first-
ly performing a Levene’s test of homoscedasticity. In all cases the variance of the data 
was not significantly different and therefore the statistical difference between mean val-
ues for treatments and controls in each experiment was determined by a linear ANOVA 
and a post hoc Bonferroni correction. 
Statistical analysis of the NF-κB data was carried out by firstly standardising the fluo-
rescence values to the same scale. Next a Levene’s test of homoscedasticity was per-
formed. Since the variance of all the data was found not to be significantly different, the 
statistical difference between mean values for pre-selected treatments and assay controls 
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was determined by ANOVA and post hoc least significant difference test with Holm-
Bonferroni (H-B) correction. Significance was set at p = 0.05/H-B correction factor. 
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                                3   Results 
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3.1 Expression of the Alpha 7 nicotinic receptor in periodontal 
tissue and oral keratinocytes 
 
3.1.1 Introduction and Aims 
 
The α7nAChR has previously been shown to be expressed by a variety of cell types 
found in the periodontium; including oral keratinocytes (Nguyen et al., 2000) and oral 
fibroblasts (Wang et al., 2010). Before we could begin to explore the possible role of 
α7nAChR in modulating the oral immune response we first investigated the expression 
of the α7nAChR in periodontal tissue and oral keratinocytes. Specifically we aimed to: 
 
-Confirm the expression of the α7nAChR in periodontal tissues and determine whether 
expression levels were elevated in periodontal disease. 
 
-Confirm the expression of α7nAChR by OKF6-TERT2 cells, in order to determine 
their suitability as a model for oral keratinocytes for subsequent in vitro investigations. 
 
 
 
3.1.2 Expression of Alpha 7 nicotinic receptor mRNA in healthy 
and diseased periodontal tissue 
 
Taqman
®
 Real time PCR using a commercially available α7nAChR primer probe set 
(Applied Biosystems, UK) was employed to confirm the expression of the α7nAChR in 
periodontal tissues and to determine if there were any differences in expression between 
healthy and diseased tissue. Figure 4 shows that α7nAChR mRNA is expressed in both 
healthy and diseased periodontal tissue and that there is a significant increase (*P<0.05) 
in α7nAChR mRNA expression in chronic periodontitis tissue samples compared to 
healthy control tissue samples. 
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Figure 4: α7nAChR mRNA expression is up regulated in the periodontal tissue of 
patients with periodontal disease. α7nAChR mRNA expression was normalised 
against a housekeeping gene; RNA Polymerase II. The data presented represents the 
mean of the normalized α7nAChR mRNA expression for the two cohorts calculated by 
the 2
-CT
 method (Schmittgen and Livak, 2008). An independent t-test was used and the 
significance level was set at p = 0.05. 
 
 
3.1.3 Expression of the Alpha 7 nicotinic receptor by primary 
oral cells  
The OKF6-TERT2 cell line represents normal oral mucosal keratinocytes which have 
been immortalized by forced expression of telomerase via retroviral transduction 
(Dickson et al., 2000). To determine their suitability as a model for in vitro studies we 
first confirmed they expressed the receptor in accordance with their primary cell coun-
terparts. Basic PCR analysis revealed that the OKF6-TERT2 cell line, similar to both 
primary oral keratinocytes and fibroblasts expressed α7nAChR mRNA (Figure 5). 
These findings were also confirmed using real time PCR (data not shown).  
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Figure 5: α7nAChR mRNA is expressed by the OKF6-TERT2 cell line as well as 
primary oral keratinocytes and fibroblasts. The primer sequence used in the PCR 
was unique for the α7nAChR and the PCR yielded products as displayed by gel electro-
phoresis at the expected size of 161 base pairs (bp). Key: lane 1: 100 bp DNA ladder, 
Lane 2: cDNA generated from primary oral keratinocytes, Lane 3: no RT control for 
primary oral keratinocytes, Lane 4: cDNA generated from primary oral fibroblasts, 
Lane 5:  no RT control for primary oral fibroblasts, Lane 6: cDNA generated from 
OKF6-TERT2 cells, Lane7: no RT control for OKF6-TERT2 cells, Lane 8: RNase free 
water PCR control, Lane 9: 100 bp DNA ladder. 
 
 
3.1.4 Conclusion 
 
The mRNA expression data shows that the α7nAChR is expressed in periodontal tis-
sues. Indeed α7nAChR mRNA is expressed by oral keratinocytes and oral fibroblasts. 
These findings are in agreement with previous studies (Nguyen et al., 2000, Wang et al., 
2010). Moreover, expression was also observed in the OKF6-TERT2 cell line. This 
finding indicates the suitability of the OKF6-TERT2 cell line as a model for oral 
keratinocytes for use in in vitro studies to explore the immuno-regulatory function of 
the α7nAChR.  
 
 
161 bp 
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3.2 The effect of the acetylcholine mimic Carbamyl chloride 
(Carbachol) on P. gingivalis induced Interleukin-8 expression by 
OKF6-TERT2 cells 
 
3.2.1 Introduction and aims 
To date, there is no direct evidence for a role of the α7nAChR in regulating the immune 
response in periodontal disease. However, the α7nAChR has been demonstrated to play 
a role in modulating the immune response of other chronic inflammatory conditions 
which are similar in their pathogenesis with PD, such as rheumatoid arthritis. Indeed, 
studies using α7nAChR-deficient (α7nAChR-/-) (Wang et al., 2003, Su et al., 2010) ani-
mals and pharmacological α7nAChR agonists/antagonists (Wang et al., 2010) have 
demonstrated the importance of this receptor in modulating the ‘cholinergic anti-
inflammatory pathway’ and controlling unrestrained inflammation in such conditions. 
Therefore, cholinergic strategies have been suggested as potential treatments for multi-
ple inflammatory diseases (Scott and Martin, 2006).   
 
Research utilizing antisense and knockout methodologies have identified an anti-
inflammatory role for the α7nAChR expressed on macrophages (Wang et al., 2003) and 
other various immune-competent epithelial cells (Greene et al., 2010). For example, in 
airway epithelial cells of cystic fibrosis, the activation of the α7nAChR was shown to 
inhibit Toll like receptor 2 (TLR-2) mediated IL-8 expression (Greene et al., 2010). In 
addition, activation of the α7nAChR was demonstrated to inhibit TNF-α induced IL-8 
expression in a human colon epithelial cell line (Summers et al., 2003). As confirmed in 
the previous section oral keratinocytes express the α7nAChR and therefore it could be 
hypothesised that a similar immunomodulatory phenomenon occurs in these cells.  
ACh is chemically unstable in vivo and in vitro and is easily degraded by acetylcholin-
esterases. For this reason ACh was not used in these in vitro studies. Neither was nico-
tine; as it is highly toxic and known to be teratogenic and carcinogenic. Therefore, Car-
bachol (Carbamyl Chloride), a stable ACh mimic, was initially used instead. Carbachol 
has been used in other in vitro studies with no evidence of toxicity and is also used clin-
ically to dilate blood vessels, stimulate intestinal peristalsis and or provoke urinary 
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bladder muscle activity (Zhou et al., 2011). More importantly, Carbachol is tolerant to 
acetylcholinesterase and therefore has a prolonged effect in vitro and in vivo. Indeed, 
studies have shown that Carbachol has an anti-inflammatory effect via the α7nAChR 
mediated cholinergic anti-inflammatory pathway. For example, it has been shown that 
Carbachol inhibits the release of proinflammatory cytokines (TNF-α and IL-6) by LPS-
stimulated rat peritoneal macrophages and human blood cells (Lu et al., 2005). There-
fore, we used Carbachol in order to explore the effects of ACh in modulating the im-
mune response of oral keratinocytes. 
In numerous in vitro studies investigating periodontal disease pathogenesis P. gingivalis 
LPS has been the stimulant of choice as P. gingivalis has been found to be the main 
causative organism of chronic periodontitis (Socransky et al., 1998). A broad range of 
virulence factors are produced by P. gingivalis, all of which contribute to the host in-
flammatory response (Birkedal-Hansen, 1993, Okada and Murakami, 1998). However, 
LPS is preferred because it is a major component of the outer membrane of P. gingivalis 
and detected by TLR-2 and TLR-4. However, despite its widespread use, P. gingivalis 
LPS has been found to have little biological potency (Dixon and Darveau, 2005). In-
deed, LPS from P. gingivalis has been shown to elicit a strikingly weak immune re-
sponse (Jain & Darveau, 2010) as it is capable  of synthesizing a heterogeneous popula-
tion of lipid A molecules, which are subtly different from each other in structure (Jain 
and Darveau, 2010). For this reason, some studies have employed heat-killed P. gingi-
valis or whole cell extracts instead of P. gingivalis LPS alone (Taylor, 2010). Studies 
using whole P. gingivalis have been shown to potently elicit the expression of IL-8 from 
a number of cell types within the periodontium (Sandros et al., 2000, Handfield et al., 
2008). This therefore suggests that using whole bacteria rather than LPS alone elicits in 
vitro a more in vivo relevant immune response in cultured cells. Data in the previous 
section confirmed that the OKF6-TERT2 cell line can be used as a suitable model for in 
vitro studies to explore the immuno-regulatory function of the keratinocyte α7nAChR. 
Therefore, the aim of this section was to:  
- Determine any cytotoxic effects of Carbachol on OKF6-TERT2 cells 
 
- Determine the effects of Carbachol in vitro on the dead P. gingivalis induced 
expression of IL-8 by the OKF6- TERT2 cell line.  
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3.2.2 The effect of Carbachol on OKF6-TERT2 cell viability 
 
Carbamyl chloride (Carbachol) is a stable acetylcholine mimic. To determine whether 
Carbachol could be used in our in vitro experiments to test the effect of targeting the 
α7nAChR on the IL-8 release from oral keratinocytes we first determined its effects on 
OKF6-TERT2 cell viability using the Cytotox-one membrane integrity assay (Promega, 
UK). Figure 6 shows that exposure to 1 – 1000 nM Carbachol had no significant effect 
on OKF6-TERT2 cell viability over a 24 hour incubation period. 
 
           
 
 
Figure 6: Viability of OKF6-TERT2 cells after exposure to varying concentrations 
of Carbachol. OKF6-TERT2 cells were cultured in a 96 well plate format at a density 
of 1 x 10
5
 cells/ml cells. The cells were treated with varying concentrations of Car-
bachol (1 nM – 1000 nM) and membrane integrity, as a marker of viability, was meas-
ured after 4 and 24 h using the CytoTox-ONE Homogenous Membrane Integrity Assay 
kit (Promega, UK). The data represents the mean ±standard deviation (SD) of duplicate 
wells from three independent experiments. (n=3).  
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3.2.3 Stimulation of OKF6-TERT2 cells with varying concentra-
tions of dead P. gingivalis to determine optimum stimulation for 
in vitro studies  
 
For the in vitro studies heat killed P. gingivalis strain ATCC 33277 was used. We first 
determined the optimal concentration of bacteria required for stimulation of IL-8 ex-
pression; in terms of number of heat killed P. gingivalis cells per OKF6-TERT2 cell 
(multiplicity of infection or MOI). Figure 7 shows the levels of IL-8 release from 
OKF6-TERT2 cells stimulated with dead P. gingivalis at 100, 200 and 300 MOI. IL-8 
release increased in a dose dependent manner. 
          
  
Figure 7: Stimulation of OKF6-TERT2 cells with varying multiplicities of infection 
of dead P. gingivalis and determination of Interleukin-8 release. In order to deter-
mine the optimal P. gingivalis MOI for the in vitro studies, OKF6-TERT2 cells were 
stimulated with 100, 200 and 300 MOI for 3, 6, 9 and 24 hrs. The data shows a signifi-
cant increase (* P<0.05) in IL-8 protein production by OKF6-TERT2 cells with an MOI 
of 100 at 9 and 24 h and at 6, 9 and 24 h with an MOI of 200 and 300.  The data shown 
is the mean expression ±standard deviation (SD) from duplicate wells of three inde-
pendent experiments (n=3). Data were tested for homoscedasticity using Levene’s test. 
Statistical differences between means were then assessed using linear ANOVA and a 
post hoc Bonferroni correction. 
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3.2.4 The effect of Carbachol on IL-8 release from OKF6-TERT2 
cells stimulated with heat killed P. gingivalis 
 
After optimising the MOI of dead P. gingivalis required to stimulate IL-8 release from 
OKF6-TERT2 cells experiments were then repeated, however on this occasion Car-
bachol was introduced into our in vitro model system. Cells were either left unstimulat-
ed, treated with 1000 nM Carbachol alone, stimulated with dead P. gingivalis alone 
(200 MOI) or first treated with varying concentrations of Carbachol for 30 min prior to 
stimulation with dead P. gingivalis (200 MOI). 
 
Figure 8 shows no effect of Carbachol (1000 nM) alone on IL-8 release. In contrast, a 
dead P. gingivalis preparation (200 cells/OKF6-TERT2 cell) caused a significant up-
regulation of IL-8 release (as seen previous: Figure 7). In the presence of varying con-
centrations of Carbachol, a slight dose dependent decrease in IL-8 release was observed. 
However, there was only a statistically significant decrease (*P<0.05) in IL-8 expres-
sion by OKF6-TERT2 cells when pre-exposed to 1000 nM Carbachol at both 6 and 9 h, 
but not 24 h. 
 
 
 
 
63 
 
                  
  
 
 
Figure 8: Carbachol inhibits IL-8 protein release from P. gingivalis stimulated 
OKF6-TERT2 cells. Cells were exposed to 3 different concentrations of Carbachol (10 
nM, 100 nM and 1000 nM) prior to stimulation with dead P. gingivalis. Cells were ex-
posed to dead P. gingivalis (200 cells/OKF6-TERT2 cell) alone or Carbachol (1000 
nM) alone for control purposes. The cells were stimulated for 3, 6, 9, 24 hrs. The data 
shown is the mean release of IL-8 ±standard deviation (SD) from duplicate wells of 
three independent experiments (n=3). Data were tested for homoscedasticity using 
Levene’s test. Statistical differences between means were then assessed using ANOVA, 
followed by a post hoc Bonferroni correction. 
 
To determine if any of the observed decreases in P. gingivalis induced IL-8 release from 
oral keratinocytes seen in figure 8 were due to regulation of IL-8 mRNA transcription, 
real time PCR was also employed on the mRNA isolated from each well. Figure 9 
shows that at 6, 9 and 24 h with 100 and 1000 nM Carbachol there was a significant de-
crease (*P<0.05) in IL-8 mRNA expression by OKF6-TERT2 cells when compared to 
cells stimulated with P. gingivalis alone. 
 
64 
 
 
 
 
 
 Figure 9: Carbachol inhibits IL-8 mRNA expression by P. gingivalis stimulated 
OKF6-TERT2 cells. OKF6-TERT2 cells were seeded into 24 well plates at a density of 
1 x10
5
 cells/ml and were exposed to 3 different concentrations of Carbachol (10 nM, 
100 nM and 1000 nM) prior to stimulation with dead P. gingivalis. Cells were exposed 
to dead P. gingivalis (200 cells/OKF6 cells) alone or Carbachol (1000 nM) alone for 
control purposes. The cells were stimulated for 3, 6, 9, 24 hrs. SYBR Green Real Time 
PCR analysis was then used to analyse the expression of IL-8 mRNA. The data shown 
is the mean IL-8 expression ±standard deviation (SD) from duplicate wells of three in-
dependent experiments (n=3). Statistical analysis was performed on the 2
-ΔCT 
values. 
Data was analysed by performing a Levene’s test on the variance of the natural log 
transformed   2
-∆ΔCT
 values followed by an independent t-test to compare two means 
(significance was set at P<0.05).  
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3.2.5 Conclusions 
 
Several studies have suggested that the anti-inflammatory role of acetylcholine is medi-
ated by the homomeric α7 subunit of nAChRs (Tracey, 2002, Wang et al., 2003, Ulloa, 
2011, de Jonge and Ulloa, 2007). These data demonstrate, using an in vitro model sys-
tem, that IL-8 expression from dead P. gingivalis stimulated OKF6-TERT2 cells was 
significantly downregulated by 1000 nM Carbachol at 6 and 9 h but not 24 h post stimu-
lation. In addition, at the mRNA level significant decreases in IL-8 mRNA expression 
were observed at 6, 9 and 24 h with 100 and 1000 nM Carbachol. This therefore sug-
gested that Carbachol can inhibit P. gingivalis induced IL-8 expression by OKF6-
TERT2 cells.  
 
Although significant differences were observed this data must be treated with caution. 
Indeed, although significant downregulated IL-8 release was observed at 6 and 9 hours 
with 1000 nM Carbachol, by 24 h expression levels seemed to recover. In addition, the 
real time PCR data, analyzing IL-8 mRNA expression, did not agree with the protein 
release data. Furthermore, there was massive variability between experiments when 
both IL-8 protein release and mRNA expression was measured. This could be due to 
experimental error. However, it is important to remember that Carbachol exerts promis-
cuity for a multitude of nicotinic and muscarinic receptors (Koelle, 1971, Miyamoto and 
Volle, 1974). Furthermore, there is evidence to suggest that different AChRs play dif-
fering roles in regulating expression of inflammatory mediators (Koval et al., 2011). A 
host of evidence suggests that mAChRs can play an opposing role to the α7nAChR and 
induce expression of proinflammatory cytokines and chemokines (Razani-Boroujerdi et 
al., 2008). Therefore as oral keratinocytes express a repertoire of both nAChRs (Nguyen 
et al., 2000) and mAChRs (Arredondo et al., 2003) it is reasonable to hypothesise that 
using pharmacologically nonspecific compounds, such as Carbachol, may elicit varying 
effects on IL-8 expression due. This may therefore go some way to explain the variabil-
ity of the results observed in our studies. Therefore, we cannot conclude from this that a 
functional α7nAChR mediated anti-inflammatory pathway operates in OKF6-TERT2 
cells.  
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3.3. The effect of the Alpha 7 nAChR specific agonist (PHA 
543613 hydrochloride) on P. gingivalis induced Interleukin-8 
expression by OKF6-TERT2 cells 
 
 
3.3.1 Introduction and Aims 
 
Data in the previous chapter did not conclusively show that activation of the α7nAChR, 
can downregulate the expression of IL-8 by OKF6-TERT2 cells stimulated by dead P. 
gingivalis. Nor did the data show that a functional α7nAChR mediated anti-
inflammatory mechanism operates in oral keratinocytes. However, as discussed previ-
ously, Carbachol is pharmacologically non-specific, as it can act on both nAChRs and 
mAChRs. When considering potential therapeutics to target the cholinergic anti-
inflammatory pathway it is important that they exhibit specificity for the α7nAChR. In 
recent years a number of α7nAChR selective agonist compounds have been investigated 
in the literature as potential therapeutics for treatment of inflammatory diseases (Rosas-
Ballina and Tracey, 2009). These compounds are capable of eliciting the cholinergic 
anti-inflammatory pathway (via activation of the α7nAChR) and have shown successful 
outcomes when applied to in vivo animal models with few unwanted side effects. These 
compounds include PHA 543613 hydrochloride, which is a potent and selective 
α7nAChR agonist. PHA 543613 hydrochloride has been identified as a potential treat-
ment of cognitive deficits in schizophrenia with an excellent in vitro profile. This com-
pound is characterized by rapid brain penetration and high oral bioavailability in rats 
and robust in vivo efficacy in a rat auditory sensory gating model (Wishka et al., 2006, 
Acker et al., 2008, Ramin et al., 2007). PHA 543613 hydrochloride has also been impli-
cated in in vivo studies investigating the anti-inflammatory role of α7nAChR in mediat-
ing neuroprotective effects through the inhibition of high mobility group box chromo-
somal protein 1 (HMGB1) (Wang et al., 2012). 
 
The mechanism by which α7nAChR can exert its anti-inflammatory effects has been 
reported to include targeting the NF-κB intracellular signaling pathway. This transcrip-
tion factor signalling pathways plays a regulatory role in inflammation. NF-κB is a key 
family of transcription factors that are widely used by cytokines to modulate gene ex-
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pression. Upon stimulation, NF-κB becomes activated in the cytoplasm, and then trans-
locates into the nucleus where it can modulate transcription of important inflammatory 
cytokines, including IL-8 (Baeuerle and Henkel, 1994, Williams et al., 2004, Matsusaka 
et al., 1993) . 
 
Nuclear factor-Kappa B (NF-κB) is a key regulator of proinflammatory gene expression 
in lymphocytes, macrophages and epithelial cells (Baeuerle and Henkel, 1994, Tak and 
Firestein, 2001). NF-κB is composed of two subunits, p50 and p65, and is retained in 
the cytoplasm of cells by a non-covalent interaction with the inhibitory molecule; Inhib-
itor of Kappa B (IkB). Upon stimulation of cells, IkB is degraded and NF-κB is released 
and translocated to the nucleus to regulate inflammatory gene expression (Lasar et al., 
2004). The key regulatory event in NF-κB activation is the phosphorylation of IkB pro-
teins by the IkB kinase (IKK) complex, which leads to IkB protein ubiquitination and 
subsequent degradation (Ghosh and Hayden, 2008). This leads to an unmasking of the 
p65 nuclear localization sequence and the released NF-κB dimers translocate to the nu-
cleus and bind to κB sites in gene promoter regions (Ghosh and Hayden, 2008). Once 
activated, inducible post-translational events allow the regulation of NF-κB transcrip-
tional activity (Chen and Greene, 2004, Schmitz et al., 2004). To date; eight different 
phosphorylation sites have been mapped for the strongly activating NF-κB p65 subunit. 
Three sites are contained in the N-terminal Rel homology domain, whereas five sites 
including (Ser468 and Ser536) are contained within both C-terminal TADs (Geng, 
2008). Basal phosphorylation of Ser468 is exerted by GSK3β (Buss et al., 2004). The 
same site can also be phosphorylated by IKKβ in response to TNFα or IL-1 stimulation 
(Schwabe and Sakurai, 2005). Moreover, phosphorylation of p65 Ser468 can be induced 
by T cell costimulation (Mattioli et al., 2004), but the responsible kinase(s) is/are not yet 
known (Mattioli et al., 2006). In nuclear translocation of p65, the phosphorylation at 
serine 536 seems to have an interesting role by defining an IκBα-independent NF-κB 
pathway (Sasaki et al., 2005). Phosphorylation of p65 NF-κB at Ser536 couples p65 to 
TAFII31-mediated transcription and is mediated, dependent on the stimulus, by various 
kinases, including IKKα/β, RSK1, TBK1 (TANK-binding kinase-1)/NAK (NF-κB-
activating kinase)/T2K (TRAF2-associated kinase), and IKKϵ (also called IKKi) (Buss 
et al., 2004, Lawrence et al., 2005). Translocation of NF-κB dimers to the nucleus re-
sults in the transcription of a myriad of proinflammatory genes, including IL-8. Most of 
them overlap with the target genes of STAT3. This is because the promoter region of 
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many of those genes contains GAS (Gamma activated sequence) or ISRE (STAT-
binding elements) in addition to κB (NF-κB binding element) sites (Bollrath and Greten, 
2009).  
 
In response to pro-inflammatory stimuli, IL-8 production is dependent on NF-κB in epi-
thelial cells (Oudin and Pugin, 2002). Indeed, stimulation of oral epithelial cells by per-
iodontal bacteria is known to activate several signal transduction cascades, including 
NF-κB (Huang et al., 2004). Recent analysis of the localization of the p50 and p65 tran-
scription factor components of the NF-κB complex demonstrated significantly increased 
activity beneath periodontal lesions (Ambili et al., 2005).  
 
In the previous chapter we used dead P. gingivalis cells in our in vitro systems instead 
of P. gingivalis LPS to be more representative of the in vivo situation. However, dental 
plaque is a polymicrobial biofilm. Planktonic cells still remain a poor substitute for the 
real challenge that host cells face from the subgingival microbial plaque biofilm. For 
this reason, in this section we applied a P. gingivalis monospecies biofilm into our in 
vitro system. This biofilm was grown on ThermanoxTM coverslips, which was then at-
tached to 24 well Millicell
®
 Cell Culture Inserts (Millipore, UK) using sterile Vaseline. 
To stimulate the previously prepared oral keratinocyte cultures the insert, with biofilm 
grown on a Thermonex
® 
coverslip attached, was suspended above the cell mono-layers 
leaving a gap of approximately 0.5 mm. This gap represents the gingival sulcus, which 
is the space existing between the tooth surface and the surrounding gingival tissues. 
Therefore, cell growth and function more closely mimic the in vivo environment.   
 
The aim of this chapter was to: 
 
- determine the cytoxicity of PHA 543613 hydrochloride, a highly selective 
α7nAChR agonist, when cultured with OKF6-TERT2 cells 
 
- determine the specific effects of PHA 543613 hydrochloride on the P. gingivalis 
monospecies biofilm induced expression of IL-8 by OKF6-TERT2 cells  
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- begin to investigate the the effects of PHA 543613 hydrochloride on NF-κB signal-
ing as a mechanism for its ability to  downregulate transcription of IL-8 in  OKF6-
TERT2 cells 
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3.3.2 The effect of PHA 543613 hydrochloride on the viability 
of OKF6-TERT2 cells 
 
PHA 543613 hydrochloride is a selective α7nAChR agonist. To determine whether 
PHA 543613 hydrochloride could be used in our in vitro experiments to test the effect 
of α7nAChR on IL-8 expression by OKF6-TERT2 cells we first determined its effects 
on cell viability using the Cytotox-one membrane integrity assay (Promega, UK). Fig-
ure 10 shows that exposure to 0.1 – 10,000 nM PHA 543613 hydrochloride had no sig-
nificant effect on OKF6-TERT2 cell viability over a 24 hour incubation period.  
                                     
  
 
 
Figure 10: Viability of OKF6-TERT2 cells after exposure to varying concentra-
tions of PHA 543613 hydrochloride. OKF6-TERT2 cells were cultured in a 96 well 
plate format at a density of 1 x 10
5
 cells/ml cells. The cells were treated with varying 
concentrations of PHA 543613 hydrochloride (0.1 nM – 10000 nM) and membrane in-
tegrity, as a marker of viability, was measured after 4 and 24 h using the CytoTox-ONE 
Homogenous Membrane Integrity Assay kit (Promega, UK). The data represents the 
mean ±standard deviation (SD) of duplicate wells from three independent experiments. 
(n=3).  
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3.3.4 The effect of PHA 543613 hydrochloride on IL-8 expres-
sion by OKF6-TERT2 cells stimulated with a live P. gingivalis 
monospecies biofilm  
 
After confirming that PHA 543613 hydrochloride was not toxic to OKF6-TERT2 cells, 
the experiments in section 3.2 were then repeated however on this occasion PHA 
543613 hydrochloride was introduced into our in vitro monospecies biofilm system. 
Cells were either left unstimulated, stimulated with a P. gingivalis monospecies biofilm 
alone, treated with 1000 nM PHA 543613 hydrochloride alone or first treated with vary-
ing concentrations of PHA 543613 hydrochloride for 30 min prior to stimulation with a 
P. gingivalis biofilm. The concentrations of PHA 543613 hydrochloride used in this in-
vestigation were determined based on the methodology of (Wang et al., 2012). 
 
Figure 11 shows that there is a significant decrease (*P<0.05) in IL-8 release by OKF6-
TERT2 cells pre-exposed to 10 nM PHA 543613 hydrochloride at 4 h and  100 nM and 
1000 nM PHA 543613 hydrochloride at 4 and 24 h. 
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Figure 11: PHA 543613 hydrochloride inhibits IL-8 protein release from P. gingi-
valis stimulated OKF6-TERT2 cells. Cells were exposed to 3 different concentrations 
of PHA 543613 hydrochloride (10 nM, 100 nM and 1000 nM) prior to stimulation with 
a P. gingivalis biofilm. Cells were exposed to a P. gingivalis monospecies biofilm alone 
or PHA 543613 hydrochloride (1000 nM) alone for control purposes. The cells were 
stimulated for 4 and 24 hrs. The data shown is the mean release of IL-8 ±standard de-
viation (SD) from duplicate wells of three independent experiments (n=3). Data were 
tested for homoscedasticity using Levene’s test. Statistical differences between means 
were then assessed using ANOVA, followed by a post hoc Bonferroni correction. 
 
To determine if any of the observed decreases in P. gingivalis induced IL-8 release from 
oral keratinocytes seen in figure 11 were due to regulation of IL-8 mRNA transcription, 
real time PCR was also employed on the mRNA isolated from each well. Figure 12 
shows that there is a significant decrease (*P<0.05) in IL-8 mRNA expression by 
OKF6-TERT2 cells pre-exposed to 10 nM PHA 543613 hydrochloride at 4 h and  100 
nM and 1000 nM PHA 543613 hydrochloride at 4 and 24 h. 
 
 
* * * * 
* 
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Figure 12: PHA 543613 hydrochloride inhibits IL-8 mRNA expression by OKF6-
TERT2 cells stimulated with a P. gingivalis monospecies biofilm. OKF6-TERT2 
cells were seeded into 24 well plates at a density of 1 x 10
5
 cells/ml and were exposed 
to 3 different concentrations of PHA 543613 hydrochloride (10 nM, 100 nM and 1000 
nM) prior to stimulation. Cells were exposed to P. gingivalis monospecies biofilm alone 
or PHA 543613 hydrochloride (1000 nM) alone for control purposes. The cells were 
stimulated for 4 and 24 hrs. SYBR Green Real Time PCR analysis was then used to 
analyse the expression of IL-8 mRNA. The data shown is the mean IL-8 expression 
±standard deviation (SD) from duplicate wells of three independent experiments (n=3). 
Statistical analysis was performed on the 2
-ΔCT 
values. Data were analysed by perform-
ing a Levene’s test on the variance of the natural log transformed 2-∆ΔCT values followed 
by an independent t-test to compare two means (significance was set at P<0.05).  
 
 
 
 
 
* * * * 
 
 
* 
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3.3.4 The effect of the Alpha 7 nicotinic receptor on the transcriptional 
activity of the Nuclear factor-kappa B (NF-κB) p65 subunit: 
 
We have demonstrated that PHA 543613 hydrochloride has a potent downregulatory 
effect on the expression of IL-8 by OKF6-TERT2 cells and that this effect is mediated 
at the transcriptional level. Therefore, to determine the pathway mediating this phenom-
enon we investigated the role of NF-κB using the FACE NF-κB p65 Profiler Kit (Active 
Motif, UK). This profiler kit specifically determines intracellular levels of phospho-
NFκB p65 (S468), phospho-NFκB p65 (S536) and the levels of total NF-κB p65 subu-
nit. The kit allows us to specifically determine the levels of the NF-κB P65 subunit 
phosphorylated at serine 468 and serine 536 in OKF6-TERT2 cells in response to stimu-
li and in the presence and absence of PHA 543613 hydrochloride.  
 
Stimulation of OKF6-TERT2 cells with P. gingivalis caused significantly elevated lev-
els of serine 468 phosphorylated NF-κB p65 subunit. However, in the presence of the 
PHA 543613 hydrochloride a concentration dependent decrease in serine 468 phos-
phorylated NF-κB p65 subunit was determined by a linear ANOVA with a significant 
difference determined observed with 1000 nM of the compound (*P=0.031) (figure 13). 
 
In addition, similar findings were observed when the levels of serine 536 phosphory-
lated NF-κB p65 subunit were investigated. Indeed, again a concentration dependent 
decrease in serine 536 phosphorylated NF-κB p65 subunit was determined by a linear 
ANOVA with a significant difference observed with 1000 nM of the compound 
(*P=0.031) (figure 14). 
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Figure 13:  Comparison of intracellular levels of the NF-B p65 subunit phosphor-
ylated at serine residue 468 in relation to total intracellular levels of the NF-B p65 
subunit. Cells were seeded into 96 well plates at a density of 1 x 10
5
 cells/well and left 
to adhere overnight at 37 
o
C with 5 % CO2. The following day, cells were stimulated for 
30 minutes with either: 1000 nM PHA-543613 HCl alone, dead (heat killed) P. gingi-
valis alone (M.O.I = 200) or in the presence of varying concentrations (10, 100, 1000 
nM) of PHA-543613 HCl. The effect of PHA-543613 HCl on the phosphorylation of 
the NF-κB p65 subunit at serine 468 was then investigated using the FACETM NF-κB 
p65 Profiler (Active Motif, UK). The % of the total NF-κB p65 subunit which was 
phosphorylated at serine 468 was then calculated in accordance with the manufacturer’s 
instructions. The % data was subjected to an angular transformation to parametric data 
for graphical representation and statistical analysis. The angular transformed data was 
subjected to Levene’s test of homoscedasticity. Since the variance of all the data was 
not significantly different the statistical difference between mean values for treatments 
and controls in each experiment was determined by linear ANOVA and a post hoc least 
significant difference test with Holm-Bonferroni (H-B) correction (significance was set 
at P=<0.05/H-B correction factor). 
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Figure 14:  Comparison of intracellular levels of the NF-B p65 subunit phosphor-
ylated at serine residue 536 in relation to total intracellular levels of the NF-B p65 
subunit. Cells were seeded into 96 well plates at a density of 1 x 10
5
 cells/well and left 
to adhere overnight at 37 
o
C with 5 % CO2. The following day, cells were stimulated for 
30 minutes with either: 1000 nM PHA-543613 HCl alone, dead (heat killed) P. gingi-
valis alone (M.O.I = 200) or in the presence of varying concentrations (10, 100, 1000 
nM) of PHA-543613 HCl. The effect of PHA-543613 HCl on the phosphorylation of 
the NF-κB p65 subunit at serine 536 was then investigated using the FACETM NF-κB 
p65 Profiler (Active Motif, UK). The % of the total NF-κB p65 subunit which was 
phosphorylated at serine 536 was then calculated in accordance with the manufacturer’s 
instructions. The % data was subjected to an angular transformation to parametric data 
for graphical representation and statistical analysis. The angular transformed data was 
subjected to Levene’s test of homoscedasticity. Since the variance of all the data was 
not significantly different the statistical difference between mean values for treatments 
and controls in each experiment was determined by linear ANOVA and a post hoc least 
significant difference test with Holm-Bonferroni (H-B) correction (significance was set 
at P=<0.05/H-B correction factor). 
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3.3.5 Conclusions 
 
In recent years a number of α7nAChR selective agonist compounds have been invest i-
gated in the literature as potential therapeutics for treatment of inflammatory diseases 
due to their fewer unwanted side effects (Rosas-Ballina and Tracey, 2009). These com-
pounds are capable of eliciting the cholinergic anti-inflammatory pathway and have 
shown successful outcomes when applied to in vivo animal models (Wishka et al., 2006, 
Acker et al., 2008, Ramin et al., 2007). In this section, using an in vitro P. gingivalis 
monospecies biofilm model and PHA 543613 hydrochloride, which is a highly selective 
α7nAChR agonist, we demonstrated that activation of the α7nAChR has a potent down-
regulatory effect on the expression of IL-8 protein by OKF6-TERT2 cells and that this 
effect is mediated at the transcriptional level.  
 
In several studies, it has been shown that α7nAChR exert its effects on immune cells (de 
Jonge et al., 2005), and macrophages (Yoshikawa et al., 2006) via triggering signaling 
mechanisms that influence the NF-κB signaling pathway. Moreover, NF-κB has been 
described as the most sensitive nAChR targets in oral keratinocytes (Arredondo et al., 
2005). Therefore, in order to determine the pathway mediating α7nAChR signaling in 
oral keratinocytes we investigated the role of NF-κB using the FACE NF-κB p65 Pro-
filer Kit (Active Motif, UK). These results demonstrate the existence a signaling mech-
anism mediating the downregulation of NF-κB phosphorylated subunits at serine resi-
due 468 and serine residue 536 through the α7nAChR selective agonist, PHA 543613 
hydrochloride. This suggests the involvement of NF-κB pathway in α7nAChR signaling 
in oral keratinocytes, thus supporting the possible therapeutic implications of α7nAChR 
in treating periodontal disease. 
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There has been extensive research in the last 10 years into the role of the α7nAChR in 
modulating the inflammatory response. ACh released by the Vagus nerve, as well as 
non-neuronal ACh, can induce an anti-inflammatory effect via the α7nAChR in various 
models of inflammatory diseases through a pathway called ‘the cholinergic anti-
inflammatory pathway’ (Pavlov and Tracey, 2005, de Jonge and Ulloa, 2007). Indeed, 
oral epithelial cells have been demonstrated to express all the components required to 
synthesise, release and respond to ACh (Nguyen et al., 2000, Grando et al., 1993, 
Rajeswari and Satyanarayana, 1990). This suggests the possibility of a role of a non-
neuronal cholinergic mechanism operating within periodontal tissue. Whether this non-
neuronal cholinergic mechanism plays a role in regulating the periodontal immune re-
sponse is unknown. However, it has previously been shown that the α7nAChR is widely 
expressed by cells found within the periodontium; including oral keratinocytes (Nguyen 
et al., 2000) and oral fibroblasts (Wang et al., 2010). In addition, the α7nAChR has also 
been shown to be expressed by infiltrating immune cells with specific roles in the path-
ogenesis of periodontal disease; including neutrophils, macrophages, B cells and T cells 
(Arredondo et al., 2006). Furthermore, there is tentative evidence to suggest that levels 
of ACh are upregulated in inflamed gingival tissues (Rajeswari and Satyanarayana, 
1990). These data therefore suggest that oral ACh and the α7nAChR may play roles in 
modulating the periodontal immune response. 
 
The data described in this thesis show that pharmacologically targeting the alpha 7 nico-
tinic receptor of oral keratinocytes can modulate their ability to express IL-8 in the pres-
ence of a known oral pathogen; P. gingivalis. P. gingivalis is thought to be a key patho-
gen driving periodontal disease pathogenesis (Darveau et al., 2012). Periodontal disease 
is chronic inflammatory disease affecting the supporting tissues of the teeth. It results 
from a dysregulated immune response to periodontal pathogens present in a multi-
species biofilm that form on the tooth surface; dental plaque (Preshaw and Taylor, 
2011). One of the early events in the pathogenesis of the disease is the influx of neutro-
phils to the site of infection. Interleukin-8 is a chemokine which plays a key role in 
promoting neutrophil migration (Bickel, 1993). It is well established that oral keratino-
cytes respond to periodontal pathogens by inducing expression of IL-8 (Huang et al., 
1998). However, for the first time the data presented here show that pharmacologically 
targeting the α7nAChR can inhibit the expression of IL-8 by oral keratinocytes induced 
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by P. gingivalis. Therefore it may be interesting to speculate that the α7nAChR is a po-
tential therapeutic target to treat PD. 
 
It is well established that oral keratinocytes express a functional α7nAChR. This was 
partially confirmed in this thesis using both conventional and real time PCR. In addi-
tion, we have confirmed that an oral keratinocyte cell line (OKF6-TERT2 cells) also 
express α7nAChR mRNA. Furthermore we have demonstrated that levels of α7nAChR 
mRNA are up regulated in tissues from patients with periodontal disease in comparison 
to healthy controls. We therefore attempted immunohistochemical analysis using a 
commercially available α7nAChR antibody (Santa Cruz, UK). However, despite ob-
served staining we could not be sure of the specificity of this antibody due to unsuccess-
ful attempts to block the staining using a commercially available blocking peptide (San-
ta Cruz, UK) (data not shown). Therefore, at present we cannot be sure which cell types 
are responsible for the up regulated α7nAChR mRNA levels observed in diseased peri-
odontal tissue. However, it is well established that a number of professional immune 
cells such as macrophages, neutrophils, T cells and B cells express the α7nAChR 
(Arredondo et al., 2006). Therefore, as diseased periodontal tissue is characterised by 
infiltration of immune cells it is interesting to speculate that these cells are responsible 
for the observed increase in α7nAChR mRNA in diseased tissue. To confirm this further 
immunoshitochemical studies would be required performing double staining with a val-
idated specific α7nAChR antibody and antibodies against known markers of each im-
mune cell subset; such as CD68/CD14 for macrophages, CD3 for T cells or neutrophil 
elastase for neutrophils. In addition, although our PCR analysis confirmed both primary 
oral keratinocytes and the OKF6-TERT2 cell line express the α7nAChR at the mRNA 
level, our data does not confirm whether this translates to a functional cell surface pro-
tein receptor. This would require immunocytochemical studies also using a validated 
α7nAChR antibody.  
 
Previous studies have demonstrated that a functional α7nAChR is expressed by oral 
keratinocytes (Arredondo et al., 2007). In recent years, it has been found that α7nAChR 
signaling has anti-inflammatory effects on epithelial cells (Summers et al., 2003, van 
Maanen et al., 2009b, Greene et al., 2010, Li et al., 2011a, Toyabe et al., 1997). There-
fore it is interesting to speculate that the α7nAChR plays similar roles in oral keratino-
cytes. Carbachol is a cholinomimetic drug that is often used as a replacement for the 
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labile acetylcholine in in vitro and in vivo studies. In a rat model of endotoxemia, Car-
bachol was shown to reduce serum levels of IL-6 and TNF-α, but not levels of the anti-
inflammatory cytokine IL-10 (Zhou et al., 2011). In addition, in vitro studies using rat 
peritoneal macrophages showed that Carbachol inhibited bacterial lipopolysaccharide 
(LPS) induced IL-6 and TNF-α in vitro (Zhou et al., 2011). Therefore, based on these 
findings we decided to use Carbachol in our in vitro model of oral keratinocyte stimula-
tion by P. gingivalis. The studies described in this thesis show that IL-8 expression is 
decreased from OKF6-TERT2 cells stimulated with dead P. gingivalis in the presence 
of Carbachol. However, a significant effect on IL-8 release at both the protein and 
mRNA level was only observed with 100 nM and 1000 nM at 6 and 9 hours and not 24 
h. One reason for this was possibly the large inter-experimental variability between re-
peats due to the initial inexperience of the researcher. This could possibly have been 
reduced by carrying out more than 3 repeat experiments to give a better indication of the 
true data distribution. This may have indicated that the use of distribution free statistical 
tests is more appropriate. Alternatively it may have determined whether transformation 
of the data would be more appropriate prior to the use of parametric tests. 
 
When pharmacologically targeting a specific receptor for therapeutic purposes it is im-
portant to consider off target effects of the compounds employed. In addition to the al-
pha 7 nicotinic receptor, oral keratinocytes express an array of nicotinic (nAChR) and 
muscarinic (mAChR) receptors. These include the α3, α5, α9, β2 and β4 nAChR recep-
tor subunits (Nguyen et al., 2000)  and the muscarinic type 2 (M2), type 3 (M3), type 4 
(M4) and type 5 (M5) receptors (Arredondo et al., 2003). Carbachol is a nonspecific 
ACh mimic which has been demonstrated to elicit its effects on an array of nicotinic 
(nAChR) and muscarinic (mAChR) receptors. Table 3 shows the reported EC50 (con-
centration of a Carbachol which induces a response halfway between the baseline and 
maximum after a specified exposure time) and Ki values (The affinity of a ligand for a 
receptor measured using a competition binding assay) for Carbachol for a host of mus-
carinic and nicotinic receptors as reported in the literature.  
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Muscarinic Receptors                    Nicotinic Receptors 
Carbachol M1 M2 M3         α7     α4β2      α3β4 
      EC50 116 + 9.9μM 1.12 + 0.10μM 8.3 μM 580 μM 17-34 μM  
(McKinney et al., 
1988) 
(McKinney et 
al., 1988) 
(Harris et 
al., 1995) 
(Anand et al., 
1993) 
(Eaton et al, 
2003) 
      Ki 90 +11 μM 8.5+3.1 μM 5.1 + 0.4 
μM 
12,000 nM 68.24+ 1.73 
nM 
3839-4700 
nM 
(McKinney et al., 
1988) 
(McKinney et 
al., 1988) 
(Jurgen 
Wess et al., 
1993) 
(Gopalakrish-
nan et al., 
1995) 
(Murali et al., 
1995) 
(Xiao&Kellar, 
2004) 
(Xiao et al., 
1998) 
 
Table 3: EC50 and Ki values for the action of carbachol against a range of muscarinic 
and nicotinic receptors. 
 
 
Due to the concentrations of Carbachol used in this thesis and the EC50 and Ki values 
described in table 3 there is the possibility that the promiscuity of Carbachol for both 
nAChRs and mAChRs (Koelle, 1971, Miyamoto and Volle, 1974) may be another rea-
son for the large inter-experimental variation observed in our studies. The role of mus-
carinic and other nicotinic receptors in inflammation is to date not well characterized.  
However, there is evidence that suggests both types of receptors play differing roles in 
inflammation (Koval et al., 2011). Indeed, there is evidence to support a pro inflamma-
tory role for muscarinic receptors (Razani-Boroujerdi et al., 2008). Oral keratinocytes 
are known to express M2, M3, M4 and M5 receptors (Arredondo et al., 2003). The 
maximal concentration of Carbachol used in this study was 1000 nM (1 µM). Based on 
the EC50 and Ki values for the M3 receptor this concentration can be hypothesised to 
have little effect on the activation of the oral keratinocyte M3 receptor. In contrast the 
EC50 value of Carbachol for the M2 receptor is much lower showing it has greater affin-
ity for this receptor. Based on the concentrations of Carbachol used in this study there-
fore we cannot discount the possibility that in the in vitro studies reported here Car-
bachol is activating M2 controlled signaling pathways. At present the role of the M2 
receptor in oral keratinocytes is not well defined. Studies have demonstrated a potential 
role in oral keratinocytes growth and differentiation (Arredondo et al., 2003). However, 
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to date no studies have investigated the role of the M2 receptor in the innate immune 
responses of oral keratinocytes to periodontal pathogens.  
 
In contrast to the muscarinic receptors, the reported EC50 value for Carbachol activation 
of the α7nAChR is 580 µM (580 times) higher than that reported for the M2 receptor). 
However, EC50 values in the literature have been calculated by varying methodologies 
from stably transfected cell lines to radioligand binding assays. In addition, the litera-
ture reporting the EC50 values for Carbachol against the α7nAChR are determined using 
transfected constructs derived from rat or mice species and not human. Therefore, at 
present the there are no rigorous studies which calculate EC50 of carbachol for the hu-
man α7nAChR. Despite this it could be concluded that in our studies we in fact used a 
concentrations of Carbachol (≤1 µM) which are significantly lower than the reported 
EC50 value in other species. However, similar studies have reported the effect of Car-
bachol in inhibiting bacterial lipopolysaccharide (LPS) induced cytokine expression in 
peritoneal macrophages macrophages (Zhou et al., 2011). Despite this fact, at present, 
based on the evidence described above we cannot conclude definitively whether the 
concentrations of Carbachol used are having a direct effect on the α7nAChR and modu-
lating the innate immune response of oral keratinocytes accordingly.  
 
To overcome the problem of receptor promiscuity, in further studies we used a potent 
and highly selective α7nAChR agonist; PHA 543613 HCl. The studies described in this 
thesis show that PHA 543613 HCl has a potent inhibitory effect on IL-8 expression by 
OKF6-TERT2 cells stimulated with a live biofilm of P. gingivalis in vitro. Cell viability 
studies demonstrated that these inhibitory effects were not due to toxic effects of the 
compound on the cells. In this study PHA 543613 HCl was used in concentrations rang-
ing from 10 - 1000 nM based on previous literature (Wang et al., 2012, Di Angelantonio 
et al., 2011). Significant inhibition of P. gingivalis induced IL-8 release and mRNA ex-
pression by oral keratinocytes was significantly inhibited in the presence of 10, 100 and 
1000 nM PHA543613 HCl. However, despite being reported to be highly selective for 
the α7nAChR, Table 4 shows that PHA 543613 HCl does have some effect on other 
nicotinic receptors;  mainly the α3β4 and α1β1γδ receptor. It is currently unknown if 
oral keratinocytes express the α1, β1, γ and δ nicotinic receptor subunits or if they pos-
sess a functional α1β1γδ receptor. In contrast, it has been reported that oral keratino-
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cytes express the α3 and β4 receptor subunits (Nguyen et al., 2000), although whether 
these cells poses a functional α3β4 receptor is yet to be proven. 
 
PHA 543613 HCl α7 α3β4 α1β1ɣδ 
EC50 24 nM  > 100 nM > 100 nM 
(Acker et al., 
2008) 
(Acker et al., 
2008) 
Ki 7 nM     
(Acker et al., 
2008) 
 
Table 4: EC50 and Ki values for the action of PHA 543613 HCl against a range of nico-
tinic receptors. 
 
 
The EC50 value for PHA 543613 HCl against the α3β4 and α1β1γδ receptor has been 
reported to be > 100 nM (Acker et al., 2008). Therefore in the studies reported in this 
thesis, if these receptors are present on oral keratinocytes, it can be inferred that the 
highest concentration of the compound used (1000 nM) may only have minimal effects 
on these receptors. In addition to the α3β4 and α1β1γδ receptors, PHA 543613 HCl has 
also been demonstrated to activate the 5-hydroxytryptamine (5-HT3:serotonin) receptor 
(Wishka et al., 2006). 5-HT3 receptors are usually found in both the peripheral (PNS) 
and central (CNS) nervous systems. Activation of these receptors in the PNS suggests 
that they play a role in a variety of sympathetic and parasympathetic sensory functions 
(Jackson and Yakel, 1995, Morales and Wang, 2002, Tecott et al., 1993). In addition, 5-
HT3 receptors are involved in information transfer in the gastrointestinal tract and in the 
enteric nervous system they regulate gut motility and peristalsis (Galligan, 2002). The 
5-HT3 receptor also play a key role in certain pathologies related to increased serotonin 
release. For example, in an in vivo mouse model persistent activation of 5-HT3 was 
shown to cause excitotoxic neuronal cell death and functional changes in the urinary 
bladder, resulting in bladder hyperdistension, urinary retention, and overflow inconti-
nence (Bhattacharya et al., 2004).  
 
The homology between orthosteric sites in α7nAChR and the 5 HT-3 receptor (Wishka 
et al., 2006), has been shown to lead to the existence of functional chimeras (Eisele et 
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al., 1993). PHA 543613 HCl has affinity for the 5-HT3 receptors with a Ki value of 628 
nM (Acker et al., 2008). However, in vitro selectivity tests have demonstrated that PHA 
543613 HCl has got at least 25-fold binding selectivity and a functional preference for 
the α7nAChR. Therefore, the relative risk of antagonism of the 5-HT3 receptor was con-
sidered to be low (Wishka et al., 2006). Moreover, there is no evidence in the literature 
demonstrating the presence of 5-HT3 receptors in the human oral tissues or on oral 
keratinocytes. Therefore, it can be tentatively be hypothesized that in our in vitro model 
system the concentrations used were selective for the α7nAChR. In order to confirm 
this, however, further studies would need to be performed. There are a number of highly 
selective α7nAChR antagonists commercially available such as methyllycaconitine cit-
rate (Abcam Biochemicals, UK)  and α-bungarotoxin (Tocris, UK), many of which have 
been used in previous experimental protocols to confirm specificity of a compound for 
the α7nAChR (Waldburger et al., 2008, Beckel et al., 2006, Shytle et al., 2006). These 
could be applied to the in vitro model systems described in this thesis and if the anti-
inflammatory response of PHA 543613 HCl is depleted in the presence of antagonists 
then specificity for the α7nAChR is confirmed. Furthermore, studies have reported the 
use of Small interfering RNA (siRNA) technology to deplete the expression of the 
α7nAChR in specific cells in vitro. Again, expression of the α7nAChR by oral keratino-
cytes could be knocked down with predesigned and validated small interfering RNA 
(siRNA) (Waldburger et al., 2008) prior to use in the in vitro model systems.  Once 
again if the anti-inflammatory response of PHA 543613 HCl is reduced when the ex-
pression of the α7nAChR is knocked down in oral keratinocytes then specificity for the 
α7nAChR can be confirmed. 
 
In this thesis data shows that one of the main mechanisms which PHA modulates the 
immune response of OKF6-TERT2 cells is through inhibited NF-κB activation. As acti-
vation of the α7nAChR has previously been shown to inhibit the immune response of 
monocytes via inhibited NF-κB activation (Yoshikawa et al., 2006) it is interesting to 
speculate that similar events occur in oral keratinocytes. NF-κB exists in cells in an in-
activated form and IL-8 gene transcription is reliant on NF-κB activation; which occurs 
through phosphorylation of the NF-κB p65 subunit and degradation of the inhibitory 
protein IκB (Matsusaka et al., 1993, Baldwin and Sharp, 1988). The data presented here 
suggests that the inhibition of IL-8 expression occurred at the level of transcription and 
activation of the α7nAChR inhibited P. gingivalis induced phosphorylation of the NF-
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κB p65 subunit at serine 468 and 536 in oral keratinocytes. Phosphorylation of the NF-
κB p65 at serine 563 has been shown to have a role in NF-κB activation (Mattioli et al., 
2004, Moreno et al., 2010). In contrast, phosphorylation at serine 468 has been shown to 
have an important role for NF-κB ubiquitination and degradation (Geng et al., 2009). 
Despite their opposing functions, phosphorylation at serine 563 and 468 occurs simulta-
neously (Moreno et al., 2010). Therefore, NF-κB activation and regulation may go hand 
in hand.  Indeed, phosphorylation of serine 468 is suggested to be a hallmark of consti-
tutively activated NF-κB in chronic inflammatory diseases (Buss et al., 2004). Phos-
phorylation of serine 563 of the NF-κB p65 subunit has been demonstrated to be im-
portant in transcription of the IL-8 gene (Buss et al., 2004). However, at present, the 
role phosphorylation of serine 468 plays in IL-8 transcription is unknown. 
 
The data described in this thesis tentatively indicate that the α7nAChR may play a role 
in PD pathogenesis. Previous studies have demonstrated that direct activation of nA-
ChRs play a role in the pathogenesis of nicotine-related periodontitis. Indeed, nicotine 
activation of nAChRs was found to enhance both IL-1β and P. gingivalis LPS induced 
IL-8 release from gingival epithelial cell lines (Kashiwagi et al., 2012). This therefore 
suggests a direct pro-inflammatory role for nicotine in periodontal disease pathogenesis. 
Indeed, in a ligature induced rat model of periodontal disease nicotine was shown to up-
regulate expression of IL-1β in periodontal ligament cells. In addition, α-bungarotoxin 
was shown to partially inhibit this phenomenon (Wang et al., 2010). This therefore sug-
gests a role for the α7nAChR in promoting inflammation; which is contradictory to the 
literature in other inflammatory diseases. However, it is important to stress that the cel-
lular effects of nicotine in the human periodontium or in animal models of periodontal 
disease have not been fully elucidated at present. Indeed, nicotine is pharmacologically 
non-specific and also has toxic side effects. As described previously, many cells, includ-
ing oral keratinocytes, express a plethora of both nAChRs and mAChRs (Nguyen et al., 
2000, Arredondo et al., 2003) whose roles in modulating inflammation have yet to be 
fully elucidated. Therefore, the use of nicotine in these reported studies may have led to 
the contradictory results obtained in these studies.  
 
In contrast to the study by Kashiwagi et al, activation of nAChRs has actually been 
shown to have a suppressive effect on periodontal immunity. Indeed, although Breivik 
et al (2009) showed that nicotine enhanced bone loss in a rat model of ligature induced 
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periodontitis, the authors did observe a smaller increase in circulating levels of pro-
inflammatory cytokines after intra-peritoneal injection of LPS in the animals treated 
with nicotine (Breivik et al., 2009). This led the authors to therefore hypothesise that 
nicotine enhances susceptibility to periodontitis through suppression of protective im-
mune responses via the ‘cholinergic anti-inflammatory pathway’. Therefore, as the im-
mune response was inhibited in these animals they failed to clear the pathogenic threat 
efficiently which led to the progression of disease. This study is therefore in agreement 
with the current accepted view of nicotine-induced periodontal disease pathogen 
(Arredondo et al., 2008b).  
 
Whether the α7nAChR is a rational target for PD therapeutic development is still a mat-
ter of debate and requires extensive research. What is clear, however, is that for target-
ing the α7nAChR to treat periodontal disease then careful consideration must be given 
in the choice of compounds utilized. This is demonstrated by the untoward effects of 
compound such as nicotine and the promiscuity of compounds such as Carbachol. As 
many resident and transient cells of the periodontium express a repertoire of both nA-
ChRs and mAChRs it can be hypothesised using pharmacologically non-specific and 
toxic compounds may elicit complex and detrimental effects in vivo. Therefore when 
considering potential therapeutics to target the cholinergic anti-inflammatory pathway 
then it is important that they exhibit specificity for the α7nAChR. In addition, although 
host response modulation offers exciting potential for the development of therapeutics 
to treat periodontal disease we must still consider that the pathogenic bacteria of plaque 
are major players in disease pathogenesis. Therefore, when considering any immuno-
modulatory strategy to treat periodontal disease the need for good oral hygiene and an-
timicrobial strategies must not be neglected. Therefore, it may be interesting to specu-
late that the use of specific α7nAChR agonists as a complement to a good oral hygiene 
regime and in conjunction with current antimicrobial therapies, rather than a standalone 
treatment, might be more efficacious in the treatment of periodontal disease. 
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